2025 the Japanese Society of Medical Oncology Annual Meeting MICEnavi

YoshimasaShiraishi{SHIRAISHIYOSHIMASA}|HidehitoHorinouchi{HORINOUCHIHIDEHITO}|YingCheng{CHENGYING}|YosukeMinami{MINAMIYOSUKE}____ShunLu{LUSHUN}|NagioTakigawa{TAKIGAWANAGIO}|ByoungChulCho{CHOBYOUNGCHUL}|HiroshiNokihara{NOKIHARAHIROSHI}|TakehitoShukuya{SHUKUYATAKEHITO}|JorgeCortes{CORTESJORGE}____TakayukiShimose{SHIMOSETAKAYUKI}|MotokoTachihara{TACHIHARAMOTOKO}|YukoTsuchiya{TSUCHIYAYUKO}|RyotaroMorinaga{MORINAGARYOTARO}|HiroyukiInoue{INOUEHIROYUKI}|YukihiroToi{TOIYUKIHIRO}|TadaakiYamada{YAMADATADAAKI}|IsamuOkamoto{OKAMOTOISAMU}|TerufumiKato{KATOTERUFUMI}|ShunichiSugawara{SUGAWARASHUNICHI}|TanakaHiroshi{HIROSHITANAKA}|TetsujiKawamura{KAWAMURATETSUJI}|HiromasaYamamoto{YAMAMOTOHIROMASA}|TakuroSakagami{SAKAGAMITAKURO}|AndresCardona{CARDONAANDRES}|TingtingXu{XUTINGTING}|LauraHiles{HILESLAURA}|DhruvitSutaria{SUTARIADHRUVIT}|MakotoNishio{NISHIOMAKOTO}|JieWang{WANGJIE}|YanYu{YUYAN}|QimingWang{WANGQIMING}|RunxiangYang{YANGRUNXIANG}|BingXia{XIABING}|ChongLi{LICHONG}|DongqingLv{LVDONGQING}|TienanYi{YITIENAN}|LiangHan{HANLIANG}|XiaoqingLiu{LIUXIAOQING}|XichengWang{WANGXICHENG}|WeiZhang{ZHANGWEI}|ManSu{SUMAN}|MinjieShen{SHENMINJIE}|JingXu{XUJING}|Bang.anPeng{PENGBANG.AN}|Jose-MariaRibera-Santasusana{RIBERA-SANTASUSANAJOSE-MARIA}|HagopKantarjian{KANTARJIANHAGOP}|IbrahimAldoss{ALDOSSIBRAHIM}|PauMontesinos{MONTESINOSPAU}|JessicaT.Leonard{LEONARDJESSICAT.}|DavidGomez-Almaguer{GOMEZ-ALMAGUERDAVID}|MariaR.Baer{BAERMARIAR.}|CarloGambacorti-Passerini{GAMBACORTI-PASSERINICARLO}|JamesMccloskey{MCCLOSKEYJAMES}|CristinaPapayannidis{PAPAYANNIDISCRISTINA}|VandersonRocha{ROCHAVANDERSON}|PhilippeRousselot{ROUSSELOTPHILIPPE}|PankitVachhani{VACHHANIPANKIT}|EuniceS.Wang{WANGEUNICES.}|LinYang{YANGLIN}|MeliessaHennessy{HENNESSYMELIESSA}|AlexanderVorog{VOROGALEXANDER}|NitiPatel{PATELNITI}|EliasJabbour{JABBOURELIAS}____Presidential Session 1Lung Cancer / Thoracic Cancer, Hematologic Malignancies____Phase II trial of Carboplatin + Nab-paclitaxel + Atezolizumab Combination for TTF-1 Negative Advanced Non-Sq NSCLC|Pharmacokinetics and safety of adjuvant alectinib in Japanese patients (pts) from ALINA with resected ALK-positive NSCLC|Phase I/II study of tifcemalimab combined with toripalimab in patients with previously treated advanced lung cancer|In-depth Responder Analysis of PhALLCON, a Phase 3 Trial of Ponatinib Versus Imatinib in Newly Diagnosed Ph+ ALL

PS1

Presidential Session 1
Lung Cancer / Thoracic Cancer, Hematologic Malignancies

HisatakaKobayashi{KOBAYASHIHISATAKA}____HironobuMinami{MINAMIHIRONOBU}________Special Lecture 1Near infrared photoimmunotherapy (NIR-PIT) of cancer____Near infrared photoimmunotherapy (NIR-PIT) of cancer

SP1

Special Lecture 1
Near infrared photoimmunotherapy (NIR-PIT) of cancer

TakashiKohno{KOHNOTAKASHI}|EdwinCuppen{CUPPENEDWIN}|KunikoSunami{SUNAMIKUNIKO}|MotohiroKato{KATOMOTOHIRO}|TatsuhiroShibata{SHIBATATATSUHIRO}____TakashiKohno{KOHNOTAKASHI}|EdwinCuppen{CUPPENEDWIN}________Presidential Symposium 1Clinical application of whole genome sequencing ____Whole genome analyses contributing to the prevention, diagnosis, and treatment of lung cancer - Introduction to the Symposium|Clinical Implementation of Whole Genome Sequencing in the Netherlands|The Current State of Clinical Implementation of Whole Genome Sequencing in Japan|Clinical applications of whole genome sequencing in childhood cancer|Clinical implementation of whole genome sequencing

PSY1

Presidential Symposium 1
Clinical application of whole genome sequencing

IzumaNakayama{NAKAYAMAIZUMA}|FilippoPietrantonio{PIETRANTONIOFILIPPO}____IzumaNakayama{NAKAYAMAIZUMA}|ElizabethSmith{SMITHELIZABETH}|FilippoPietrantonio{PIETRANTONIOFILIPPO}|YukihideKanemitsu{KANEMITSUYUKIHIDE}|YoshiakiNakamura{NAKAMURAYOSHIAKI}|HirokiOsumi{OSUMIHIROKI}|ItaruYasufuku{YASUFUKUITARU}____CarolinaSciortino{SCIORTINOCAROLINA}|GiuliaMontelatici{MONTELATICIGIULIA}|AndreaBottelli{BOTTELLIANDREA}|VincenzoNasca{NASCAVINCENZO}____Symposium 1New multimodal treatment strategy for GI cancer____Redefining the Path to Cure: The Rise of Non-Operative Management in Upper GI Cancer|NONOPERATIVE MANAGEMENT IN LOWER GI CANCERS

SY1

Symposium 1
New multimodal treatment strategy for GI cancer

BhumsukKeam{KEAMBHUMSUK}|NaokiFukuda{FUKUDANAOKI}|TomohiroEnokida{ENOKIDATOMOHIRO}|Ken-IchiIto{ITOKEN-ICHI}____TomoyaYokota{YOKOTATOMOYA}|HishamMehanna{MEHANNAHISHAM}________Symposium 2Current Status and Prospects of Treatment Strategies for Thyroid Cancer____Recent updates in molecular targeted agents for thyroid cancer|Current status of systemic therapy for radioiodine-refractory differentiated thyroid cancer|Current status and future perspectives on the treatment of anaplastic thyroid caner|Current Status and Prospects of Treatment Strategies for Thyroid Cancer in Japan

SY2

Symposium 2
Current Status and Prospects of Treatment Strategies for Thyroid Cancer

SadakatsuIkeda{IKEDASADAKATSU}|TatsuyaSuzuki{SUZUKITATSUYA}|JunkoTakita{TAKITAJUNKO}|ShinsukeAmano{AMANOSHINSUKE}|TakashiOshio{OSHIOTAKASHI}____ManabuMuto{MUTOMANABU}|KatsutoshiOda{ODAKATSUTOSHI}________Presidential Symposium 2How to use uninsured medicines recommended by genomic medicine?____Challenges and Future Opportunities in Drug Access for Precision Cancer Medicine in Japan|Off-Label Drug Use under Japanese Health Insurance System|Current Status of Off-Label Drug Use in Pediatric Oncology|Off-label drug use for cancer patients|Health insurance system and new drug coverage in Japan

PSY2

Presidential Symposium 2
How to use uninsured medicines recommended by genomic medicine?

TakehitoShukuya{SHUKUYATAKEHITO}|YosukeMinami{MINAMIYOSUKE}____SeijiYano{YANOSEIJI}|TetsujiTakayama{TAKAYAMATETSUJI}________Highlight of the Day【Thoracic Oncology / Hematology Oncology】Highlight of the Day 1____－

HoD1

Highlight of the Day【Thoracic Oncology / Hematology Oncology】
Highlight of the Day 1

SeishiOgawa{OGAWASEISHI}|HiroyoshiNishikawa{NISHIKAWAHIROYOSHI}|MasaakiIto{ITOMASAAKI}|SatoshiNishizuka{NISHIZUKASATOSHI}|YozoNakazawa{NAKAZAWAYOZO}|TetsujiNaka{NAKATETSUJI}____TakashiKohno{KOHNOTAKASHI}|ManabuMuto{MUTOMANABU}|SeijiYano{YANOSEIJI}________Joint Symposium 1（JCA / JSCO / JSMO）JCA/JSCO/JSMO initiatives for precision oncology____Biomarkers for CLK inhibitor CTX-712 treatment response in myeloid neoplasms: Paving the way toward clinical trials|Elucidation of the Resistance Mechanisms to Cancer Immunotherapy|Prospects for navigation surgery using AI technology|Longitudinal Tumor-Informed ctDNA Dynamics for Monitoring Tumor Burden in Advanced Cancers|Development of novel CAR-T cell therapy: from blood cancers to solid tumors|Development of a novel antibody-drug conjugate with a CAF-mediated mechanism of action targeting Glypican-1

JS1

Joint Symposium 1（JCA / JSCO / JSMO）
JCA/JSCO/JSMO initiatives for precision oncology

HironobuMinami{MINAMIHIRONOBU}|IsseiKomuro{KOMUROISSEI}____HironobuMinami{MINAMIHIRONOBU}________Special SessionImportance and Reality of Oncocardiology based on Komuro Group Study____Oncologists should learn onco-cardiology|Current status and issues in onco-cardiology practice as revealed by a survey of the Ministry of Health, Labour and Welfare Science Research Fund

SS

Special Session
Importance and Reality of Oncocardiology based on Komuro Group Study

MarekTrneny{TRNENYMAREK}|MinoruKanaya{KANAYAMINORU}|WonSeogKim{KIMWONSEOG}|CortesEJorge{JORGECORTESE}____NorikoFukuhara{FUKUHARANORIKO}|KazuyukiShimada{SHIMADAKAZUYUKI}|EiseiKondo{KONDOEISEI}|SatoshiIyama{IYAMASATOSHI}____MichaelWang{WANGMICHAEL}|WojciechJurczak{JURCZAKWOJCIECH}|DavidBelada{BELADADAVID}|TomaszWrobel{WROBELTOMASZ}|NilanjanGhosh{GHOSHNILANJAN}|Mary-MargaretKeating{KEATINGMARY-MARGARET}|TomVanMeerten{VANMEERTENTOM}|RubenFernandezAlvarez{FERNANDEZALVAREZRUBEN}|GottfriedVonKeudell{VONKEUDELLGOTTFRIED}|CatherineThieblemont{THIEBLEMONTCATHERINE}|FredericPeyrade{PEYRADEFREDERIC}|MarcAndre{ANDREMARC}|MarcHoffmann{HOFFMANNMARC}|EdithSzafer-Glusman{SZAFER-GLUSMANEDITH}|JenniferLin{LINJENNIFER}|JamesP.Dean{DEANJAMESP.}|JuttaK.Neuenburg{NEUENBURGJUTTAK.}|ConstantineS.Tam{TAMCONSTANTINES.}|JacobD.Soumerai{SOUMERAIJACOBD.}|ChanY.Cheah{CHEAHCHANY.}|MaryAnnAnderson{ANDERSONMARYANN}|MasaLasica{LASICAMASA}|EmmaVerner{VERNEREMMA}|StephenS.Opat{OPATSTEPHENS.}|ShuoMa{MASHUO}|RobertWeinkove{WEINKOVEROBERT}|RaulCordoba{CORDOBARAUL}|PaoloGhia{GHIAPAOLO}|SophieLeitch{LEITCHSOPHIE}|DavidWesterman{WESTERMANDAVID}|SheelPatel{PATELSHEEL}|YiqianFang{FANGYIQIAN}|WeiDing{DINGWEI}|RonitGurion{GURIONRONIT}|IritAvivi{AVIVIIRIT}|AndrasMasszi{MASSZIANDRAS}|AlejandroMartinGarcia-Sancho{GARCIA-SANCHOALEJANDROMARTIN}|ZsoltNagy{NAGYZSOLT}|BenoitTessoulin{TESSOULINBENOIT}|AnaJimenezUbieto{UBIETOANAJIMENEZ}|Po-ShenKo{KOPO-SHEN}|DanielAlanKerr{KERRDANIELALAN}|EdwinEJeng{JENGEDWINE}|SatyaSiddani{SIDDANISATYA}|NehaJoshi{JOSHINEHA}|NehaDixit{DIXITNEHA}|MarianaSacchi{SACCHIMARIANA}|PegahJafarinasabian{JAFARINASABIANPEGAH}|AbrahamAvigdor{AVIGDORABRAHAM}|GhayasCIssa{ISSAGHAYASC}|RichardALarson{LARSONRICHARDA}|TimothyPHughes{HUGHESTIMOTHYP}|AndreasHochhaus{HOCHHAUSANDREAS}|NaotoTakahashi{TAKAHASHINAOTO}|FeliceBombaci{BOMBACIFELICE}|JianxiangWang{WANGJIANXIANG}|Dong-WookKim{KIMDONG-WOOK}|DennisDongHwanKim{DONGHWANKIMDENNIS}|EnnanGu{GUENNAN}|YifanZhang{ZHANGYIFAN}|ShrutiKapoor{KAPOORSHRUTI}|NithyaAgrawal{AGRAWALNITHYA}|RajendraJinwal{JINWALRAJENDRA}|AndreaDamon{DAMONANDREA}|IslamSadek{SADEKISLAM}____Oral Session 1Hematologic Malignancies____Ibrutinib Plus Venetoclax in Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis of the Phase 3 SYMPATICO Study|Sonrotoclax + Zanubrutinib Has High uMRD Rates and Good Tolerability in Ongoing Phase 1/1b Study in Treatment-Naive CLL|Epcoritamab + Lenalidomide (E-Len) in Patients with Relapsed/Refractory (R/R) DLBCL: Updated Results from EPCORE NHL-5|Tolerability of Asciminib vs Investigator-Selected (IS) TKIs in Phase 3 ASC4FIRST Study in Newly Diagnosed CML Patients

O1

Oral Session 1
Hematologic Malignancies

MikioMukai{MUKAIMIKIO}|YoichiNaito{NAITOYOICHI}|KazuhiroBandai{BANDAIKAZUHIRO}|YoshihiroTanaka{TANAKAYOSHIHIRO}|TatsuhiroShibata{SHIBATATATSUHIRO}|YoshihisaNakagawa{NAKAGAWAYOSHIHISA}____YukoTanabe{TANABEYUKO}|YoshihiroFukumoto{FUKUMOTOYOSHIHIRO}____TaroShiga{SHIGATARO}|YujiOkura{OKURAYUJI}|HiroshKusaba{KUSABAHIROSH}|YoshihiroFukumoto{FUKUMOTOYOSHIHIRO}____Joint Symposium 2（JCS / JOCS / JSMO）Timing of consulting cardiologists in cancer treatment and subsequent follow-up____Differences between oncologists and cardiologists regarding the indications for invasive treatment of cardiovascular disease in cancer patients|Cancer care and follow-up: When to consult a cardiologist|The role of hematologists in providing care to patients with cardio-oncology problems|Cancer associated thrombosis: Multidisciplinary collaboration and follow-up|Enhancing Efficiency in Cardio-Oncology Clinics: Addressing the Growing Burden of CV Complications in Cancer Patients|A Cardiovascular Interventionalist’s Perspective

JS2

Joint Symposium 2（JCS / JOCS / JSMO）
Timing of consulting cardiologists in cancer treatment and subsequent follow-up

KennosukeKarube{KARUBEKENNOSUKE}|NathanFowler{FOWLERNATHAN}|YosukeMinami{MINAMIYOSUKE}|JorgeECortes{CORTESJORGEE}____KennosukeKarube{KARUBEKENNOSUKE}|YosukeMinami{MINAMIYOSUKE}________Symposium 3Cutting edge of genomic medicine and novel therapy in hematologic malignancies____Utilization of cancer genome medicine in the pathological diagnosis of lymphoid neoplasms|From Biomarker Discovery to Clinical Decision Making: Multi-Omic Approaches in Non-Hodgkin Lymphoma (NHL)|Genomic profiling and Precision Medicine for Leukemia Therapy|Novel therapy based on genomic analysis in leukemia

SY3

Symposium 3
Cutting edge of genomic medicine and novel therapy in hematologic malignancies

AkiraChiba{CHIBAAKIRA}|AkiraHirasawa{HIRASAWAAKIRA}|TakeshiKuwata{KUWATATAKESHI}|MotohiroKato{KATOMOTOHIRO}|IzumiOkawara{OKAWARAIZUMI}____IsseiImoto{IMOTOISSEI}|KatsuyaTsuchihara{TSUCHIHARAKATSUYA}________Joint Symposium 3（JSHG / JSMO）Next generation Presicion oncology and genetic medicine ____Cancer Genomic Medicine in Japan|Guidance for hereditary cancer syndrome with multigene panel testing (MGPT) ver. 2025|Presumed Germline Pathogenic Variant|Significance and future prospects for clinical implementation of whole genome sequencing|Expectation for clinical implementation of MGPT and Patient and public involvement in MGPT

JS3

Joint Symposium 3（JSHG / JSMO）
Next generation Presicion oncology and genetic medicine

TakayukiYoshino{YOSHINOTAKAYUKI}|HisatoKawakami{KAWAKAMIHISATO}|YasutoshiKuboki{KUBOKIYASUTOSHI}____SatoshiYuki{YUKISATOSHI}|AkihitoKawazoe{KAWAZOEAKIHITO}|HannekeVanLaarhoven{LAARHOVENHANNEKEVAN}|YukiyaNarita{NARITAYUKIYA}____TakeshiKato{KATOTAKESHI}|YingYuan{YUANYING}|TarohSatoh{SATOHTAROH}|JingdongZhang{ZHANGJINGDONG}|DaisukeKotani{KOTANIDAISUKE}|KenseiYamaguchi{YAMAGUCHIKENSEI}|AtsuoTakashima{TAKASHIMAATSUO}|HiroyaTaniguchi{TANIGUCHIHIROYA}|KentaroYamazaki{YAMAZAKIKENTARO}|HirokiHara{HARAHIROKI}|KoichiSuyama{SUYAMAKOICHI}|YujiMiyamoto{MIYAMOTOYUJI}|SakamotoYasuhiro{YASUHIROSAKAMOTO}|ElvisCela{CELAELVIS}|TianChen{CHENTIAN}|MingLei{LEIMING}|LixianJin{JINLIXIAN}|JinLi{LIJIN}|JenethAquino{AQUINOJENETH}|ArvindDasari{DASARIARVIND}|CathyEng{ENGCATHY}|ZijiYu{YUZIJI}|LucyChen{CHENLUCY}|AlbertoSobrero{SOBREROALBERTO}|ManishRSharma{SHARMAMANISHR}|JohnStrickler{STRICKLERJOHN}|DavidSommerhalder{SOMMERHALDERDAVID}|RuthPerets{PERETSRUTH}|JonathanCohen{COHENJONATHAN}|JudithRaimbourg{RAIMBOURGJUDITH}|TakakoEguchiNakajima{EGUCHINAKAJIMATAKAKO}|NoboruYamamoto{YAMAMOTONOBORU}|MarciaCruz-Correa{CRUZ-CORREAMARCIA}|O'neilBertH{BERTHO'NEIL}|FrançoisGhiringhelli{GHIRINGHELLIFRANÇOIS}|KanwalRaghav{RAGHAVKANWAL}|RachelRuiLi{LIRACHELRUI}|GladysOrrison-Thiele{ORRISON-THIELEGLADYS}|MarthaNeaguAristide{ARISTIDEMARTHANEAGU}|KevinJ.Freise{FREISEKEVINJ.}|CarlaBiesdorf{BIESDORFCARLA}|AthanVasilopoulos{VASILOPOULOSATHAN}|JohnPowderly{POWDERLYJOHN}____Oral Session 2Gastrointestinal Cancer 1____Nivolumab + ipilimumab vs chemotherapy in MSI-H/dMMR metastatic colorectal cancer: CheckMate 8HW Asian subgroup analysis|ECOG performance status deterioration with fruquintinib in metastatic colorectal cancer: Post hoc analysis of FRESCO-2|ABBV-400, a novel c-Met-targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer

O2

Oral Session 2
Gastrointestinal Cancer 1

HiroyukiShibata{SHIBATAHIROYUKI}|TatsuyaTakagi{TAKAGITATSUYA}|HisayasuNagakura{NAGAKURAHISAYASU}|KazunariAbe{ABEKAZUNARI}|ShinobuUto{UTOSHINOBU}|TeruhisaAzuma{AZUMATERUHISA}____TetsuhiroYoshinami{YOSHINAMITETSUHIRO}|ChieWatanabe{WATANABECHIE}____AkiraKawai{KAWAIAKIRA}|HirotakaKawano{KAWANOHIROTAKA}|MitsuhisaAzuma{AZUMAMITSUHISA}|ShigemiMatsumoto{MATSUMOTOSHIGEMI}|EijiNakata{NAKATAEIJI}|YasunoriArai{ARAIYASUNORI}|KeiIto{ITOKEI}|EisukeKobayashi{KOBAYASHIEISUKE}|HideoMorioka{MORIOKAHIDEO}|SayakaYamaguchi{YAMAGUCHISAYAKA}____Symposium 4Tumor board for patients with bone metastasis - management of a conference that maximize multidisciplinary expertise-____Issues and problems with bone metastasis cancer boards|Transdisciplinary management of skeletal metastasis in cancer patients|The Role of Radiation Oncologists in Bone Metastasis Conferences|As active role of rehabilitation therapists at the meeting of multiple professionals for the patient with bone metastasis|The Role of Nurses in the Multidisciplinary Management of Bone Metastasis in Cancer|Let’s make it happen in the hospital! ~Know-how to organize a bone metastasis conference ~

SY4

Symposium 4
Tumor board for patients with bone metastasis - management of a conference that maximize multidisciplinary expertise-

NintitaSThokanit{THOKANITNINTITAS}|ShinichiroFukahori{FUKAHORISHINICHIRO}|KazuhiroTsuruta{TSURUTAKAZUHIRO}|KeitaMiyashita{MIYASHITAKEITA}____TerufumiKato{KATOTERUFUMI}|JunyaSato{SATOJUNYA}|KenichiSuzuki{SUZUKIKENICHI}|TomomiFujisawa{FUJISAWATOMOMI}____JirapaOn-Aree{ON-AREEJIRAPA}|TanapolThonkamdee{THONKAMDEETANAPOL}|EkaphopSirachainan{SIRACHAINANEKAPHOP}|TomokiSakakida{SAKAKIDATOMOKI}|ChihoKudo{KUDOCHIHO}|AkinobuOgawa{OGAWAAKINOBU}|JunkoKurono{KURONOJUNKO}|EriHotta{HOTTAERI}|AkimitsuMaeda{MAEDAAKIMITSU}|MatsuuraYukiko{YUKIKOMATSUURA}|MayumiYamaguchi{YAMAGUCHIMAYUMI}|ChisatoYamada{YAMADACHISATO}|MasashiAndo{ANDOMASASHI}|IsaoOze{OZEISAO}|HiroyaTaniguchi{TANIGUCHIHIROYA}|TetsuyaKatori{KATORITETSUYA}|HisayoHujimura{HUJIMURAHISAYO}|SachiMorimoto{MORIMOTOSACHI}|DanTakeuti{TAKEUTIDAN}|TakaakiKaneko{KANEKOTAKAAKI}|SeikiMiura{MIURASEIKI}|JyunichiroKamiya{KAMIYAJYUNICHIRO}|ChizuYamada{YAMADACHIZU}|NorikazuKitagawa{KITAGAWANORIKAZU}|HiroeHuse{HUSEHIROE}|MasakoInoue{INOUEMASAKO}|EtsukoOzaki{OZAKIETSUKO}|MizukiKatsuura{KATSUURAMIZUKI}|AkinobuAoki{AOKIAKINOBU}|YoichiUnno{UNNOYOICHI}|TaroNakasima{NAKASIMATARO}|NozomiSakai{SAKAINOZOMI}|MasayoKomoda{KOMODAMASAYO}|YasukoIshihara{ISHIHARAYASUKO}|JunichiHiguchi{HIGUCHIJUNICHI}|KotaroKobayashi{KOBAYASHIKOTARO}|SachikoFurutani{FURUTANISACHIKO}|KenjiNishimura{NISHIMURAKENJI}|ShinichiNishina{NISHINASHINICHI}|ToshikazuMoriwaki{MORIWAKITOSHIKAZU}|ReikoArisawa{ARISAWAREIKO}|KazunobuTakayanagi{TAKAYANAGIKAZUNOBU}____Oral Session 3Multidisciplinary Team Program____Improving Survival in Hepatocellular Carcinoma: The Benefits of Multidisciplinary Team Involvement|Evaluating safety and outcomes of midline catheters for cancer patients receiving 5-FU chemotherapy(MLC45FU study)|A Randomized Controlled Trial of Usefulness of Electronic Patient Reported Outcome for FN in Patients with Cancer|Hospitalization-required irAEs in cancer patients on immune checkpoint inhibitors: a single institution experience

O3

Oral Session 3
Multidisciplinary Team Program

KojiMatsumoto{MATSUMOTOKOJI}|YasunariOkuda{OKUDAYASUNARI}|YoutaYatagai{YATAGAIYOUTA}|HidekiYanome{YANOMEHIDEKI}|ToshikiNakamura{NAKAMURATOSHIKI}|HisanoriShimizu{SHIMIZUHISANORI}____TomonobuKoizumi{KOIZUMITOMONOBU}|JunyaSato{SATOJUNYA}________Symposium 5Next-generation regimen management through multi-disciplinary collaboration____How to implement feasible and evidence-based chemotherapy regimen|The Role of Pharmacists in Managing Cancer Chemotherapy Regimens|Incorporating safe administration management from a nurse’s perspective into regimen reviews|Effectiveness of Dietitian Interventions in Cancer Chemotherapy Review Committee|Possible roles of pharmacists in health insurance pharmacies with disclosure of drug dosage regimens by hospitals|Pharmaceutical management leading to the AI hospital projects

SY5

Symposium 5
Next-generation regimen management through multi-disciplinary collaboration

BibianaJozefiakova{JOZEFIAKOVABIBIANA}|GabrielBanik{BANIKGABRIEL}|MatusAdamkovic{ADAMKOVICMATUS}|RyanCHarliman{HARLIMANRYANC}|YohYamaguchi{YAMAGUCHIYOH}|HirokiOkumura{OKUMURAHIROKI}____DaisukeSakai{SAKAIDAISUKE}|HiromichiMatsuoka{MATSUOKAHIROMICHI}____MichalKentos{KENTOSMICHAL}|IvanaPiterova{PITEROVAIVANA}|MiroslavaBozoganova{BOZOGANOVAMIROSLAVA}|DenisaFedakova{FEDAKOVADENISA}|MatusAdamkovic{ADAMKOVICMATUS}|LubicaZibrinova{ZIBRINOVALUBICA}|ViktoriaMajdakova{MAJDAKOVAVIKTORIA}|JaroslavaBocanova{BOCANOVAJAROSLAVA}|MariaDedova{DEDOVAMARIA}|BibianaJozefiakova{JOZEFIAKOVABIBIANA}|DominikaHavrillova{HAVRILLOVADOMINIKA}|GabrielBanik{BANIKGABRIEL}|AbimanyuSakh{SAKHABIMANYU}|AryaMSimanjuntak{SIMANJUNTAKARYAM}|NicolasSachio{SACHIONICOLAS}|ZerulikaPNursari{NURSARIZERULIKAP}|AyskaNZamzami{ZAMZAMIAYSKAN}|TatsuyaYoshida{YOSHIDATATSUYA}|SayakaArakawa{ARAKAWASAYAKA}|HirotoIshiki{ISHIKIHIROTO}|RyokoHigashiyama{HIGASHIYAMARYOKO}|KenMasuda{MASUDAKEN}|YukiShinno{SHINNOYUKI}|YusukeOkuma{OKUMAYUSUKE}|YasushiGoto{GOTOYASUSHI}|HidehitoHorinouchi{HORINOUCHIHIDEHITO}|NoboruYamamoto{YAMAMOTONOBORU}|ErikoSatomi{SATOMIERIKO}|YuichiroOhe{OHEYUICHIRO}|ShukoSoma{SOMASHUKO}|YosukeAoyama{AOYAMAYOSUKE}|YuHarada{HARADAYU}|KiyomiNonogaki{NONOGAKIKIYOMI}|HarukaKono{KONOHARUKA}|ErisaToda{TODAERISA}|HarukaOzaki{OZAKIHARUKA}|MasahiroKuno{KUNOMASAHIRO}|ShogoWatanabe{WATANABESHOGO}|KazumasaYamamoto{YAMAMOTOKAZUMASA}|KohjiTakemura{TAKEMURAKOHJI}|TakeshiYamaguchi{YAMAGUCHITAKESHI}|YukoTanabe{TANABEYUKO}|AtsushiYokoyama{YOKOYAMAATSUSHI}|KoichiSuyama{SUYAMAKOICHI}|KojiHashiguchi{HASHIGUCHIKOJI}|YujiMiura{MIURAYUJI}____Mini Oral Session 1Palliative Care / Symptom Management 1 (Psycho-Oncology)____Exploring the Relationship Between Resilience and Posttraumatic Growth in Cancer Patients|Depression and Anxiety in Patients with Cancer: Exploring the Role of Coping Resources through a Network Approach|Posttraumatic Growth in Cancer Patients: Understanding the Mechanism via the Network Analysis Approach|A Systematic Review of Symptom Management and Psycho-Oncology in Palliative Care for Colorectal Cancer Patients|Impact of Social Isolation on the clinical outcomes in advanced NSCLC patients|Gender Differences in Chemotherapy-Induced Alopecia Distress Using Japanese Chemotherapy-Induced Alopecia Distress Scale

MO1

Mini Oral Session 1
Palliative Care / Symptom Management 1 (Psycho-Oncology)

KazuakiKushi{KUSHIKAZUAKI}|KeikoOgawa{OGAWAKEIKO}|KazukiShimada{SHIMADAKAZUKI}|KazuhiroAraki{ARAKIKAZUHIRO}|YuyaKawaguchi{KAWAGUCHIYUYA}|NokitakaSetsu{SETSUNOKITAKA}____MasakazuAbe{ABEMASAKAZU}|TomofumiMiura{MIURATOMOFUMI}____YoshinobuMatsuda{MATSUDAYOSHINOBU}|NorikoFujiwara{FUJIWARANORIKO}|NobuhisaNakajima{NAKAJIMANOBUHISA}|KeiichiNarita{NARITAKEIICHI}|ShunsukeOyamada{OYAMADASHUNSUKE}|KeisukeAriyoshi{ARIYOSHIKEISUKE}|IchimaruKatsuaki{KATSUAKIICHIMARU}|KeisukeKaneishi{KANEISHIKEISUKE}|RitsukoYabuki{YABUKIRITSUKO}|NatsukiKanno{KANNONATSUKI}|HiroyukiKohara{KOHARAHIROYUKI}|TetsushiTsuruga{TSURUGATETSUSHI}|TaeKinoshita{KINOSHITATAE}|MasayaKinjo{KINJOMASAYA}|MasatoNakajima{NAKAJIMAMASATO}|HirokiSugawara{SUGAWARAHIROKI}|NanakoNishiyama{NISHIYAMANANAKO}|HengyangLi{LIHENGYANG}|NozomuMurakami{MURAKAMINOZOMU}|YumiIkejiri{IKEJIRIYUMI}|YasuhikoTatsuzawa{TATSUZAWAYASUHIKO}|KeisukeYamada{YAMADAKEISUKE}|HirofumiHirana{HIRANAHIROFUMI}|YukinaKotaka{KOTAKAYUKINA}|KeitaMori{MORIKEITA}|HidekiIshikawa{ISHIKAWAHIDEKI}|HiroshiHaneda{HANEDAHIROSHI}|KiyokazuTakeuchi{TAKEUCHIKIYOKAZU}|YuichiroNishibori{NISHIBORIYUICHIRO}|ReoOmori{OMORIREO}|YukiNakatani{NAKATANIYUKI}|YukoAkaishi{AKAISHIYUKO}|AyakoTanaka{TANAKAAYAKO}|KoheiAkiyoshi{AKIYOSHIKOHEI}|ShinyaTokunaga{TOKUNAGASHINYA}|HarukoDaga{DAGAHARUKO}|SuguruFukushima{FUKUSHIMASUGURU}|TomohiroNishijima{NISHIJIMATOMOHIRO}|TaitoEsaki{ESAKITAITO}____Mini Oral Session 2Palliative Care / Symptom Management 2 (Palliative Medicine)____RCT and observational study on the efficacy of specialized rehabilitation for cancer patients in palliative care units|The effect of contact needle therapy on fatigue in palliative care: a randomized controlled trial|Evaluation of pain in cancer patients using the AI app for cancer palliative care support, PalliEase|Clinical Utility of Inflammation and Nutrition biomarkers of immune checkpoint inhibitors in Advanced Cancer|Relationship between hypovolemia from dysphagia and cisplatin-induced acute kidney injury in esophageal cancer patients|Adherence to Recommended Osteoporosis Treatment Reduces Fracture Risk in Cancer Patients

MO2

Mini Oral Session 2
Palliative Care / Symptom Management 2 (Palliative Medicine)

PrihantiniPrihantini{PRIHANTINIPRIHANTINI}|KazumasaMogi{MOGIKAZUMASA}|LauraLiao{LIAOLAURA}|QuangAnhNguyen{NGUYENQUANGANH}____Jae-WeonKim{KIMJAE-WEON}|KoseiHasegawa{HASEGAWAKOSEI}|MayuYunokawa{YUNOKAWAMAYU}|TadaakiNishikawa{NISHIKAWATADAAKI}____AndiNursantiAUreng{URENGANDINURSANTIA}|RolandHelmizar{HELMIZARROLAND}|SahnazVPutri{PUTRISAHNAZV}|RifaldyFajar{FAJARRIFALDY}|MasatoYoshihara{YOSHIHARAMASATO}|RyoEmoto{EMOTORYO}|EmiriMiyamoto{MIYAMOTOEMIRI}|HirokiFujimoto{FUJIMOTOHIROKI}|KanameUno{UNOKANAME}|ShoheiIyoshi{IYOSHISHOHEI}|KazuhisaKitami{KITAMIKAZUHISA}|NobuhisaYoshikawa{YOSHIKAWANOBUHISA}|ShigeyukiMatsui{MATSUISHIGEYUKI}|HiroakiKajiyama{KAJIYAMAHIROAKI}|JingHe{HEJING}|YutakaKaneko{KANEKOYUTAKA}|KokiKabu{KABUKOKI}|TracyMichener{MICHENERTRACY}|JeffreyAnderson{ANDERSONJEFFREY}|NarguessAskari{ASKARINARGUESS}|TriChinhLe{LETRICHINH}|TatKhanhThieu{THIEUTATKHANH}____Oral Session 4Gynecologic Cancer____AI-Driven Identification of ecDNA-Mediated Mechanisms Underlying Platinum Resistance in High-Grade Serous Ovarian Cancer|Histology-specific long-term oncologic outcomes in epithelial ovarian cancer patients who underwent complete resection|Real-world characteristics and treatment patterns of patients with recurrent or metastatic cervical cancer in Japan|RESULTS OF TREATMENT FOR OVARIAN CANCER OF THE GRANULOSA CELL TYPE AT VIETNAM NATIONAL CANCER HOSPITAL

O4

Oral Session 4
Gynecologic Cancer

MayuYunokawa{YUNOKAWAMAYU}|OmaliPitiyarachchi{PITIYARACHCHIOMALI}|－|DanielAng{ANGDANIEL}____KojiNishino{NISHINOKOJI}|KasumiYamamoto{YAMAMOTOKASUMI}____AkikoAbe{ABEAKIKO}|GyohiOh{OHGYOHI}|TakehiroNakao{NAKAOTAKEHIRO}|KeiKato{KATOKEI}|RisakoOzawa{OZAWARISAKO}|YusukeToyohara{TOYOHARAYUSUKE}|MotokoKanno{KANNOMOTOKO}|SachihoNetsu{NETSUSACHIHO}|TerumiTanigawa{TANIGAWATERUMI}|HidetakaNomura{NOMURAHIDETAKA}|NaomiHayashi{HAYASHINAOMI}|IppeiFukada{FUKADAIPPEI}|HiroyukiKanao{KANAOHIROYUKI}|ShunjiTakahashi{TAKAHASHISHUNJI}|MichaelFriedlander{FRIEDLANDERMICHAEL}|KeXinBok{BOKKEXIN}|ShingLihWong{WONGSHINGLIH}|YihanLi{LIYIHAN}|YenChengYeo{YEOYENCHENG}|AdelePcWong{WONGADELEPC}|IeeraMAggarwal{AGGARWALIEERAM}|JackJChan{CHANJACKJ}____Mini Oral Session 3Gynecologic Cancer 1____The clinical course of Immune check point inhibitor for Gynecologic cancer with MS-H/dMMR/TMB-H|Age disparities in poly(ADP-ribose) polymerase (PARP) inhibitor trials in high grade serous ovarian cancer (HGSOC)|Withdrawn|Second-line Trastuzumab Deruxtecan for Metastatic HER2-Expressing Gastric-Type Mucinous Carcinoma of Cervix in Singapore

MO3

Mini Oral Session 3
Gynecologic Cancer 1

HiroakiInui{INUIHIROAKI}|－|TherdpongThongseiratch{THONGSEIRATCHTHERDPONG}|HastiHTolani{TOLANIHASTIH}____KojiMatsumoto{MATSUMOTOKOJI}|JungYunLee{LEEJUNGYUN}____TomotakaNakagawa{NAKAGAWATOMOTAKA}|TomohiroKagawa{KAGAWATOMOHIRO}|TakeshiIwasa{IWASATAKESHI}|NutthapornChandeying{CHANDEYINGNUTTHAPORN}|ClarissaACendera{CENDERACLARISSAA}|EmilyWOtto{OTTOEMILYW}|AndreeKurniawan{KURNIAWANANDREE}|IanHuang{HUANGIAN}____Mini Oral Session 4Gynecologic Cancer 2____Verification of treatment for VAIN diagnosed after TLH for CIN3|Withdrawn|Behavioral Economics for Cervical Cancer Prevention Programs: A Meta-Analysis and Qualitative Comparative Analysis|Evaluating the efficacy and safety of pembrolizumab in dMMR and pMMR patients with advanced endometrial cancer

MO4

Mini Oral Session 4
Gynecologic Cancer 2

Jung-YunLee{LEEJUNG-YUN}|ShannonNWestin{WESTINSHANNONN}|KathleenNMoore{MOOREKATHLEENN}____KanYonemori{YONEMORIKAN}|Jae-WeonKim{KIMJAE-WEON}________Symposium 6New drug treatments for gynecological cancers____How Clinical Trials Enhance Patient Outcomes in Cervical Cancer|State of Art Treatment of Advanced and Recurrent Endometrial Cancer: Immunotherapy and Beyond|New Drug Treatments for Ovarian Cancer

SY6

Symposium 6
New drug treatments for gynecological cancers

TaizoHirata{HIRATATAIZO}|AkihiroHirakawa{HIRAKAWAAKIHIRO}|YoshiyukiMajima{MAJIMAYOSHIYUKI}|TakashiOwa{OWATAKASHI}|ToyotakaIguchi{IGUCHITOYOTAKA}____KanYonemori{YONEMORIKAN}|KiyohitoNakai{NAKAIKIYOHITO}________Presidential Symposium 3Open discussion for the revisonof conditional approval system from Ministry of Health, Labour and Welfare in 2024____From the standpoint of academia|From the Perspective of Biostatistics and Regulatory Science|Utilizing and Improving the Conditional Approval System from the Perspective of Patient Benefits|From the industry’s perspective|Making everyone’s lives brighter together ~From the Regulator’s Perspective~

PSY3

Presidential Symposium 3
Open discussion for the revisonof conditional approval system from Ministry of Health, Labour and Welfare in 2024

ErikaP.Hamilton{HAMILTONERIKAP.}|AnnaSpreafico{SPREAFICOANNA}|HideakiBando{BANDOHIDEAKI}|TakafumiKoyama{KOYAMATAKAFUMI}____LynnSchuchter{SCHUCHTERLYNN}|HironobuMinami{MINAMIHIRONOBU}____TadayoshiHashimoto{HASHIMOTOTADAYOSHI}|TaroShibuki{SHIBUKITARO}|TakaoFujisawa{FUJISAWATAKAO}|MitsuhoImai{IMAIMITSUHO}|ShinKobayashi{KOBAYASHISHIN}|JunichiroYuda{YUDAJUNICHIRO}|MichikoNagamine{NAGAMINEMICHIKO}|ShingoSakashita{SAKASHITASHINGO}|RiuYamashita{YAMASHITARIU}|TakeshiKuwata{KUWATATAKESHI}|YoshiakiNakamura{NAKAMURAYOSHIAKI}|AtsushiOhtsu{OHTSUATSUSHI}|TakayukiYoshino{YOSHINOTAKAYUKI}____ASCO/JSMO Joint SymposiumDrugging the Undruggable Targets____Breaking Barriers: Advances in targeting the “undruggable” proteins in oncology|Unlocking Undraggable Targets: from Mission Impossible to Mission Achievable|SCRUM-MONSTAR Multiomics Platform: Advancing Precision Medicine through Novel Cancer Therapeutics|The development of drugs targeting RNA splicing mechanisms in anti-cancer therapy

AJS

ASCO/JSMO Joint Symposium
Drugging the Undruggable Targets

YosukeTogashi{TOGASHIYOSUKE}|KiichiroNinomiya{NINOMIYAKIICHIRO}|HidetoshiHayashi{HAYASHIHIDETOSHI}|SatoruMiura{MIURASATORU}|YasushiGoto{GOTOYASUSHI}____YosukeTogashi{TOGASHIYOSUKE}|YasushiGoto{GOTOYASUSHI}________Symposium 7How do we select the partner for the combination immunotherapy?____How Do We Select the Partner for Combination Immunotherapy?|The role of cytotoxic chemotherapy in combination immunotherapy|CTLA-4: Established Target, Next Antibodies, and Persistent Unknowns|The role of anti-angiogenic therapy in tumor immunity|Strategic Partnering in Cancer Immunotherapy

SY7

Symposium 7
How do we select the partner for the combination immunotherapy?

StevenOlsen{OLSENSTEVEN}|MasahiroSekiguchi{SEKIGUCHIMASAHIRO}|TatsukiIkoma{IKOMATATSUKI}|NobuakiMatsubara{MATSUBARANOBUAKI}____KazutoNishio{NISHIOKAZUTO}|NatsukoChiba{CHIBANATSUKO}|WataruOkamoto{OKAMOTOWATARU}|YoheiFunakoshi{FUNAKOSHIYOHEI}____MichinaMorioka{MORIOKAMICHINA}|SadakatsuIkeda{IKEDASADAKATSU}|YoshihiroGocho{GOCHOYOSHIHIRO}|YujiYamada{YAMADAYUJI}|YokoShioda{SHIODAYOKO}|ChikakoKiyotani{KIYOTANICHIKAKO}|KeitaTerashima{TERASHIMAKEITA}|DaisukeTomizawa{TOMIZAWADAISUKE}|KimikazuMatsumoto{MATSUMOTOKIMIKAZU}|KoichiYagi{YAGIKOICHI}|HiroshiKobayashi{KOBAYASHIHIROSHI}|KenyaKobayashi{KOBAYASHIKENYA}|TakakoYoshioka{YOSHIOKATAKAKO}|AyaUshiku{USHIKUAYA}|TetsuoUshiku{USHIKUTETSUO}|HidenoriKage{KAGEHIDENORI}|KatsutoshiOda{ODAKATSUTOSHI}|YuichiShiraishi{SHIRAISHIYUICHI}|SeiyaImoto{IMOTOSEIYA}|KunikoSunami{SUNAMIKUNIKO}|MotohiroKato{KATOMOTOHIRO}|ShogenBoku{BOKUSHOGEN}|TomoyoYasuda{YASUDATOMOYO}|NobuhiroShibata{SHIBATANOBUHIRO}|MasashiKanai{KANAIMASASHI}|TakayasuKurata{KURATATAKAYASU}|DesamparadosRoda{RODADESAMPARADOS}|Jean-PascalMachiels{MACHIELSJEAN-PASCAL}|ChangFangChui{CHUICHANGFANG}|ShunsukeKondo{KONDOSHUNSUKE}|VictorAdornoFebles{ADORNOFEBLESVICTOR}|VictorMoreno{MORENOVICTOR}|Chia-ChiLin{LINCHIA-CHI}|SunYoungRha{RHASUNYOUNG}|DavidSarid{SARIDDAVID}|AlbiruniAbdulRazak{ABDULRAZAKALBIRUNI}|StevenKao{KAOSTEVEN}|MaulikPatel{PATELMAULIK}|MohammadSahtout{SAHTOUTMOHAMMAD}|JonathanDeutsch{DEUTSCHJONATHAN}|DuyenNgo{NGODUYEN}|CristianoFerlini{FERLINICRISTIANO}|KaiHe{HEKAI}____Oral Session 5Translational Research / Clinical Pharmacology____Real-world application of comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) in Japan and East Asia|Prospective observational study to conduct whole genome sequencing for cancer patients: a progress report|Age-Related Trends in Druggable Genetic Alterations Across Major Solid Tumors: Analysis of C-CAT Data|Livmoniplimab and budigalimab for advanced solid tumors: Results from dose expansion cohort for urothelial carcinoma

O5

Oral Session 5
Translational Research / Clinical Pharmacology

HiromichiEbi{EBIHIROMICHI}|TakafumiKoyama{KOYAMATAKAFUMI}|AkihitoKawazoe{KAWAZOEAKIHITO}|ChigusaMorizane{MORIZANECHIGUSA}|Woong-YangPark{PARKWOONG-YANG}____YoshiakiNakamura{NAKAMURAYOSHIAKI}|YuSunakawa{SUNAKAWAYU}________Symposium 8Challenges for implementation of translational research in clinical trials____Multiomics analysis using a large-scale sample set from clinical trials|Translational Research in Early Drug Development|Translational research in gastrointestinal cancer using clinical samples|Challenges for implementation of translational research in large scale investigator-initiated clinical trials|Spatial architecture of tumor microenvironment and therapeutic responses

SY8

Symposium 8
Challenges for implementation of translational research in clinical trials

MasashiWakabayashi{WAKABAYASHIMASASHI}|KazunoriTakemura{TAKEMURAKAZUNORI}|SadakatsuIkeda{IKEDASADAKATSU}|YukikoHibino{HIBINOYUKIKO}|ToshioOgawa{OGAWATOSHIO}|HiroakiIkushima{IKUSHIMAHIROAKI}____HideoHarigae{HARIGAEHIDEO}|NobuakiMatsubara{MATSUBARANOBUAKI}|TakashiShimamoto{SHIMAMOTOTAKASHI}|TomonoriMizutani{MIZUTANITOMONORI}____TakashiIkeno{IKENOTAKASHI}|HidekiFuruya{FURUYAHIDEKI}|SeikoMatsuda{MATSUDASEIKO}|SuzueTerao{TERAOSUZUE}|JunkiMizusawa{MIZUSAWAJUNKI}|MiyuKato{KATOMIYU}|CaseyCanizio{CANIZIOCASEY}|AiKawana{KAWANAAI}|JunichiroSawa{SAWAJUNICHIRO}|AyakaSano{SANOAYAKA}|NatsumiUeda{UEDANATSUMI}|AkinoYoshihara{YOSHIHARAAKINO}|YayoiKondo{KONDOYAYOI}|TakanoriTsuda{TSUDATAKANORI}|HiromiSasamoto{SASAMOTOHIROMI}|KenMatsui{MATSUIKEN}|JunichiMano{MANOJUNICHI}|KojiAndo{ANDOKOJI}|JotaroShinagawa{SHINAGAWAJOTARO}|NorihiroGunji{GUNJINORIHIRO}|KaoriNishiyama{NISHIYAMAKAORI}|NaokiSugiyama{SUGIYAMANAOKI}|YasunariShiokawa{SHIOKAWAYASUNARI}|JyunkoYokobori{YOKOBORIJYUNKO}|ShoichiKanayama{KANAYAMASHOICHI}|HajimeShingu{SHINGUHAJIME}|TatsunoriShimoi{SHIMOITATSUNORI}|HitomiOkuma{OKUMAHITOMI}|AyumuArakawa{ARAKAWAAYUMU}|KanYonemori{YONEMORIKAN}|TeruhikoYoshida{YOSHIDATERUHIKO}|SachieIshibashi{ISHIBASHISACHIE}|YoshiyukiSano{SANOYOSHIYUKI}|SatoruSekiya{SEKIYASATORU}|KazutakaTogashi{TOGASHIKAZUTAKA}|LijuanHuang{HUANGLIJUAN}|AkikoIkeda{IKEDAAKIKO}|KazuhikoAoyagi{AOYAGIKAZUHIKO}|FumitakaTakeshita{TAKESHITAFUMITAKA}|AkinobuHamada{HAMADAAKINOBU}|KousukeWatanabe{WATANABEKOUSUKE}|AyaShinozaki-Ushiku{SHINOZAKI-USHIKUAYA}|KatsutoshiOda{ODAKATSUTOSHI}|HidenoriKage{KAGEHIDENORI}____Oral Session 6Clinical Trial Facilitation Program____Using hybrid trial-design approach in confirmatory non-inferiority trial for anti-cancer treatment|The status and challenges of “drug loss” in Japan, analyzed from survey to pharmaceutical companies conducted by CRO|Development of a Novel Clinical Trial Search System for Genetic Abnormality Detected by Comprehensive Genomic Profiling|Importance of collaboration between Clinical Research Core Hospitals and other hospitals to accelerate clinical trials|An evaluation of the “10-Year Strategy for Cancer Research”|A machine learning-based analysis of nationwide CGP data to identify features associated with mutation-based therapy

O6

Oral Session 6
Clinical Trial Facilitation Program

YasutoshiKuboki{KUBOKIYASUTOSHI}|HidekazuHirano{HIRANOHIDEKAZU}|HiroyukiTakeda{TAKEDAHIROYUKI}|YueWang{WANGYUE}|HanbingWang{WANGHANBING}|YusukeMiyajima{MIYAJIMAYUSUKE}____YoshiakiNagatani{NAGATANIYOSHIAKI}|HiroshiImazeki{IMAZEKIHIROSHI}____JudithRaimbourg{RAIMBOURGJUDITH}|FrançoisGhiringhelli{GHIRINGHELLIFRANÇOIS}|JonathanECohen{COHENJONATHANE}|ChiyoeKitagawa{KITAGAWACHIYOE}|ManishSharma{SHARMAMANISH}|KiHyeongLee{LEEKIHYEONG}|MaríaJoseDeMiguel{MIGUELMARÍAJOSEDE}|ZoëN.Hunter{HUNTERZOËN.}|MichaelBurns{BURNSMICHAEL}|RuiLi{LIRUI}|NandiniRudra-Ganguly{RUDRA-GANGULYNANDINI}|CarlaBiesdorf{BIESDORFCARLA}|KevinJ.Freise{FREISEKEVINJ.}|MarthaBlaney{BLANEYMARTHA}|GladysMorrison-Thiele{MORRISON-THIELEGLADYS}|MarthaNeaguAristide{ARISTIDEMARTHANEAGU}|JohnStrickler{STRICKLERJOHN}|TakeruWakatsuki{WAKATSUKITAKERU}|NorikoYamamoto{YAMAMOTONORIKO}|NaokiIshizuka{ISHIZUKANAOKI}|ShuichiHironaka{HIRONAKASHUICHI}|KeikoMinashi{MINASHIKEIKO}|ShigenoriKadowaki{KADOWAKISHIGENORI}|HirokazuShoji{SHOJIHIROKAZU}|MasahiroGoto{GOTOMASAHIRO}|ToshifumiYamaguchi{YAMAGUCHITOSHIFUMI}|KeishoChin{CHINKEISHO}|MarikoOgura{OGURAMARIKO}|IzumaNakayama{NAKAYAMAIZUMA}|HirokiOsumi{OSUMIHIROKI}|ArisaUeki{UEKIARISA}|ShigehisaKitano{KITANOSHIGEHISA}|NarikazuBoku{BOKUNARIKAZU}|KenseiYamaguchi{YAMAGUCHIKENSEI}|DaisukeTakahari{TAKAHARIDAISUKE}|RyoheiKawabata{KAWABATARYOHEI}|AtsushiIshiguro{ISHIGUROATSUSHI}|ShinichiNishina{NISHINASHINICHI}|MasazumiTakahashi{TAKAHASHIMASAZUMI}|ShuheiSuzuki{SUZUKISHUHEI}|TakahisaSuzuki{SUZUKITAKAHISA}|JinMatsuyama{MATSUYAMAJIN}|YasufumiOtsuki{OTSUKIYASUFUMI}|YusukeAkamaru{AKAMARUYUSUKE}|NaokiTakegawa{TAKEGAWANAOKI}|TakashiNomura{NOMURATAKASHI}|YosukeKito{KITOYOSUKE}|HiroshiYabusaki{YABUSAKIHIROSHI}|YujiNegoro{NEGOROYUJI}|AkitakaMakiyama{MAKIYAMAAKITAKA}|MasatoNakamura{NAKAMURAMASATO}|MasakiTakahashi{TAKAHASHIMASAKI}|YuSunakawa{SUNAKAWAYU}|YaweiChen{CHENYAWEI}|YutaoWei{WEIYUTAO}|JuYang{YANGJU}|XiaoyuZhou{ZHOUXIAOYU}|QinLiu{LIUQIN}|YangYang{YANGYANG}|WenxianGuan{GUANWENXIAN}|BaoruiLiu{LIUBAORUI}|JiaWei{WEIJIA}|ShiTao{TAOSHI}|WangYue{YUEWANG}|LuoYuting{YUTINGLUO}|PanYunfeng{YUNFENGPAN}|ZhouXiaoyu{XIAOYUZHOU}|ZhangYue{YUEZHANG}|LiuBaorui{BAORUILIU}|WeiJia{JIAWEI}|TakeshiKawakami{KAWAKAMITAKESHI}|SatoshiSuzuki{SUZUKISATOSHI}|KunihiroFushiki{FUSHIKIKUNIHIRO}|KotoeOshima{OSHIMAKOTOE}|AkihiroOhba{OHBAAKIHIRO}|TakahiroTsushima{TSUSHIMATAKAHIRO}|SatoshiHamauchi{HAMAUCHISATOSHI}|TomoyaYokota{YOKOTATOMOYA}|YusukeOnozawa{ONOZAWAYUSUKE}|HirofumiYasui{YASUIHIROFUMI}|KentaroYamazaki{YAMAZAKIKENTARO}____Mini Oral Session 5Gastrointestinal Cancer 1 (Gastric Cancer 1 Basic）____Telisotuzumab Adizutecan (ABBV-400), a c-Met-Targeting ADC, in Pts With Advanced GEA: Results From a Phase 1 Study|Complementary Relationship Between ERBB2 and Other Oncogenes Amplifications (Amp) in HER2 positive Gastric Cancer (GC)|Clinical Features and Evolution of Actionable Genomic Alterations in Recurrent Gastric/Gastroesophageal Junction Cancer|Biomarkers of Neoadjuvant Anti-PD-1 in Combination with Chemoradiotherapy for LocallyAdvanced G/GEJ Adenocarcinoma|Fatty acid synthesis inhibition synergizes with PD1 blockade by regulating suppressive macrophages in gastric cancer|The impact of prior nivolumab on the treatment outcomes of taxane plus ramucirumab for advanced gastric cancer

MO5

Mini Oral Session 5
Gastrointestinal Cancer 1 (Gastric Cancer 1 Basic）

KenseiYamaguchi{YAMAGUCHIKENSEI}|HirokazuShoji{SHOJIHIROKAZU}|NaotoshiSugimoto{SUGIMOTONAOTOSHI}|YosukeKito{KITOYOSUKE}|TheodoraConstantinaEAdeodatia{ADEODATIATHEODORACONSTANTINAE}|AmosIChandra{CHANDRAAMOSI}____YasushiTsuji{TSUJIYASUSHI}|YasunoriEmi{EMIYASUNORI}____HirokazuShoji{SHOJIHIROKAZU}|HisateruYasui{YASUIHISATERU}|EijiOki{OKIEIJI}|DaisukeSakai{SAKAIDAISUKE}|TetsuyaHamaguchi{HAMAGUCHITETSUYA}|JianningYang{YANGJIANNING}|AbrahamGuerrero{GUERREROABRAHAM}|YokoUeno{UENOYOKO}|MariaMatsangou{MATSANGOUMARIA}|GeorgiaGourgioti{GOURGIOTIGEORGIA}|YukaNakanishi{NAKANISHIYUKA}|SatomiFuruki{FURUKISATOMI}|KanaKuwamoto{KUWAMOTOKANA}|ShunsukeYamada{YAMADASHUNSUKE}|KoheiShitara{SHITARAKOHEI}|KenseiYamaguchi{YAMAGUCHIKENSEI}|AkihitoTsuji{TSUJIAKIHITO}|TakashiOshima{OSHIMATAKASHI}|MasahiroTsuda{TSUDAMASAHIRO}|KeikoMinashi{MINASHIKEIKO}|KokiNakanishi{NAKANISHIKOKI}|YasuhiroKodera{KODERAYASUHIRO}|HisatoKawakami{KAWAKAMIHISATO}|AkitakaMakiyama{MAKIYAMAAKITAKA}|HirotakaKonishi{KONISHIHIROTAKA}|SatoshiMorita{MORITASATOSHI}|YukiyaNarita{NARITAYUKIYA}|MotohiroImano{IMANOMOTOHIRO}|RinInamoto{INAMOTORIN}|TomohiroNishina{NISHINATOMOHIRO}|TakeshiKawakami{KAWAKAMITAKESHI}|MotohisaHagiwara{HAGIWARAMOTOHISA}|HirokiKume{KUMEHIROKI}|KeitaYamaguchi{YAMAGUCHIKEITA}|WataruHashimoto{HASHIMOTOWATARU}|KeiMuro{MUROKEI}|NozomuOgura{OGURANOZOMU}|MisaOhnishi{OHNISHIMISA}|KengoNagashima{NAGASHIMAKENGO}|NaokiTakahashi{TAKAHASHINAOKI}|MitsuhiroFuruta{FURUTAMITSUHIRO}|NozomuMachida{MACHIDANOZOMU}|Kho,JesselyneASantoso{SANTOSOKHO,JESSELYNEA}|JasonMPrawira{PRAWIRAJASONM}|ClarissaACedera{CEDERACLARISSAA}|AndreeKurniawan{KURNIAWANANDREE}|HeruSKoerniawan{KOERNIAWANHERUS}|CharistaLBudiputri{BUDIPUTRICHARISTAL}|JacobusJWibisono{WIBISONOJACOBUSJ}____Mini Oral Session 6Gastrointestinal Cancer 2 (Gastric Cancer 2 Trial）____Zolbetuximab Plus mFOLFOX6 in Japanese Patients With Gastric or Gastroesophageal Junction Adenocarcinoma (SPOTLIGHT)|Zolbetuximab Plus CAPOX in Japanese Patients With Gastric or Gastroesophageal Junction Adenocarcinoma (GLOW Trial)|Prognostic Factors for T-DXd Treatment in HER2+ Unresectable Advanced/Recurrent Gastric Cancer: EN-DEAVOR Sub-Analysis|Correlation between PD-L1 CPS and efficacy of Nivo-CT for gastric or GEJ cancer: a multi-center retrospective study|Overall Survival and Progression Free Survival of Pembrolizumab in Patients Advance Gastric Cancer : A Meta Analysis|Safety and Efficacy of Nivolumab for Gastric Cancer: A Meta-Analysis and Trial Sequential Analysis of Clinical Trials

MO6

Mini Oral Session 6
Gastrointestinal Cancer 2 (Gastric Cancer 2 Trial）

HirokiSato{SATOHIROKI}|HiroyukiOhnuma{OHNUMAHIROYUKI}|SakditadSaowapa{SAOWAPASAKDITAD}|KevinWong{WONGKEVIN}|UlilAlbabHabibah{HABIBAHULILALBAB}|KeishoChin{CHINKEISHO}____ShunsukeKagawa{KAGAWASHUNSUKE}|NaotoshiSugimoto{SUGIMOTONAOTOSHI}____WataruIchikawa{ICHIKAWAWATARU}|KazuhiroYoshida{YOSHIDAKAZUHIRO}|YasuhiroKodera{KODERAYASUHIRO}|YoshihiroKakeji{KAKEJIYOSHIHIRO}|MitsuguKochi{KOCHIMITSUGU}|HitoshiOjima{OJIMAHITOSHI}|KazumasaFujitani{FUJITANIKAZUMASA}|JunHihara{HIHARAJUN}|NobuyukiMusha{MUSHANOBUYUKI}|AtsushiIshiguro{ISHIGUROATSUSHI}|MasatoKitazawa{KITAZAWAMASATO}|TsuyoshiSano{SANOTSUYOSHI}|TakahiroToyokawa{TOYOKAWATAKAHIRO}|ShinichiKinami{KINAMISHINICHI}|YusukeTaki{TAKIYUSUKE}|MasahiroTakeuchi{TAKEUCHIMASAHIRO}|YuSunakawa{SUNAKAWAYU}|MasashiFujii{FUJIIMASASHI}|TakeshiSano{SANOTAKESHI}|NoritoSuzuki{SUZUKINORITO}|MasanoriSato{SATOMASANORI}|YutakaOkagawa{OKAGAWAYUTAKA}|KazuyukiMurase{MURASEKAZUYUKI}|TadashiOgawa{OGAWATADASHI}|TatsuyaIto{ITOTATSUYA}|YujiAkiyama{AKIYAMAYUJI}|KoichiTakada{TAKADAKOICHI}|NatchayaPolpichai{POLPICHAINATCHAYA}|ManasaweeTanariyakul,{TANARIYAKUL,MANASAWEE}|ChalothornWannaphut{WANNAPHUTCHALOTHORN}|HectorJoseGarciaPleitez{GARCIAPLEITEZHECTORJOSE}|DiegoOlavarriaBernal{OLAVARRIABERNALDIEGO}|PojsakornDanpanichkul{DANPANICHKULPOJSAKORN}|ChanakarnKanitthamniyom{KANITTHAMNIYOMCHANAKARN}|PanatYanpiset{YANPISETPANAT}|NarathornKulthamrongsri{KULTHAMRONGSRINARATHORN}|ThanathipSuenghataiphorn{SUENGHATAIPHORNTHANATHIP}|NangInnPunKham{PUNKHAMNANGINN}|PiengpitchTakayama{TAKAYAMAPIENGPITCH}|PharitSiladech{SILADECHPHARIT}|LukmanTijani{TIJANILUKMAN}|NaokiIshizuka{ISHIZUKANAOKI}|RyoheiKawabata{KAWABATARYOHEI}|HisashiHosaka{HOSAKAHISASHI}|OsamuMuto{MUTOOSAMU}|YoshiakiShindo{SHINDOYOSHIAKI}|NaokiNagata{NAGATANAOKI}|HiroshiYabusaki{YABUSAKIHIROSHI}|HiroshiImamura{IMAMURAHIROSHI}|ShunjiEndo{ENDOSHUNJI}|TomomiKashiwada{KASHIWADATOMOMI}|MasatoNakamura{NAKAMURAMASATO}|11{11}|MichiyaKobayashi{KOBAYASHIMICHIYA}|FumioNagashima{NAGASHIMAFUMIO}|DaisukeTakahari{TAKAHARIDAISUKE}|KenseiYamaguchi{YAMAGUCHIKENSEI}____Mini Oral Session 7Gastrointestinal Cancer 3（Gastric Cancer 3　Surgical Department）____Prediction of prognosis in stage III gastric cancer patients: Random survival forest analysis from the START-2 trial|Long-term prognostic value of conversion surgery for unresectable gastric cancer: a propensity score matching analysis|Mortality Disparities in Hospitalized Gastric Cancer Patients with Protein-Calorie Malnutrition by Gender and Race in US|Discovery of Escapee tumour (ET) cells and its long term implication in gastric cancer|Comparison of surgical outcomes between robotic gastrectomy versus laparoscopic gastrectomy in gastric cancer patients|CapeOX for Elderly Patients with Advanced Gastric Cancer; Analysis for Appropriate G8 Cut-off Value for Survival

MO7

Mini Oral Session 7
Gastrointestinal Cancer 3（Gastric Cancer 3　Surgical Department）

AkinariTsukada{TSUKADAAKINARI}|GoSaito{SAITOGO}|ByoungChulCho{CHOBYOUNGCHUL}|KiyotakaYoh{YOHKIYOTAKA}|XiuningLe{LEXIUNING}____MakotoNishio{NISHIOMAKOTO}|NobuyukiYamamoto{YAMAMOTONOBUYUKI}|MotokoTachihara{TACHIHARAMOTOKO}|EikiIchihara{ICHIHARAEIKI}____ChieMorita{MORITACHIE}|YusakuKusaba{KUSABAYUSAKU}|YoshieTsujimoto{TSUJIMOTOYOSHIE}|AkaneIshida{ISHIDAAKANE}|MasaoHashimoto{HASHIMOTOMASAO}|ManabuSuzuki{SUZUKIMANABU}|JinTakasaki{TAKASAKIJIN}|NaokiNishimura{NISHIMURANAOKI}|HiroshiNokihara{NOKIHARAHIROSHI}|ShinyuIzumi{IZUMISHINYU}|MasayukiHojo{HOJOMASAYUKI}|HidekazuSuzuki{SUZUKIHIDEKAZU}|YasushiGoto{GOTOYASUSHI}|KenTajima{TAJIMAKEN}|HiromiNagashima{NAGASHIMAHIROMI}|TetsunariHase{HASETETSUNARI}|TakaakiSasaki{SASAKITAKAAKI}|YasutakaWatanabe{WATANABEYASUTAKA}|HirotsuguKenmotsu{KENMOTSUHIROTSUGU}|ShoichiItoh{ITOHSHOICHI}|MasafumiYamaguchi{YAMAGUCHIMASAFUMI}|MarieMatsumoto{MATSUMOTOMARIE}|YosukeSeto{SETOYOSUKE}|KenUchibori{UCHIBORIKEN}|HidetoshiHayashi{HAYASHIHIDETOSHI}|EisakuMiyauchi{MIYAUCHIEISAKU}|NaokiIshizuka{ISHIZUKANAOKI}|YusukeKajihara{KAJIHARAYUSUKE}|YukiNakagawa{NAKAGAWAYUKI}|RyoheiKatayama{KATAYAMARYOHEI}|Se-HoonLee{LEESE-HOON}|EnriquetaFelip{FELIPENRIQUETA}|AlexanderISpira{SPIRAALEXANDERI}|NicolasGirard{GIRARDNICOLAS}|YuJungKim{KIMYUJUNG}|YuriyOstapenko{OSTAPENKOYURIY}|PongwutDanchaivijitr{DANCHAIVIJITRPONGWUT}|BaogangLiu{LIUBAOGANG}|AdlindaAlip{ALIPADLINDA}|KiHyeongLee{LEEKIHYEONG}|HailinXiong{XIONGHAILIN}|SoonHinHow{HOWSOONHIN}|YingCheng{CHENGYING}|Gee-ChenChang{CHANGGEE-CHEN}|JamesChih-HsinYang{YANGJAMESCHIH-HSIN}|BenjaminBesse{BESSEBENJAMIN}|JoshuaMBauml{BAUMLJOSHUAM}|ShunLu{LUSHUN}|KiyotakaYoh{YOHKIYOTAKA}|YanYu{YUYAN}|YanqiuZhao{ZHAOYANQIU}|DavidPlanchard{PLANCHARDDAVID}|XingyaLi{LIXINGYA}|ShirishGadgeel{GADGEELSHIRISH}|AlexanderSpira{SPIRAALEXANDER}|JonathanRiess{RIESSJONATHAN}|SatoruKitazono{KITAZONOSATORU}|NatashaLeighl{LEIGHLNATASHA}|BoGao{GAOBO}|OscarJuan-Vidal{JUAN-VIDALOSCAR}|AdrianusJohannesDeLangen{JOHANNESDELANGENADRIANUS}|JulienMazieres{MAZIERESJULIEN}|YongJiang{JIANGYONG}|StevenYea{YEASTEVEN}|JieWang{WANGJIE}____Oral Session 7Lung Cancer / Thoracic Cancer 1____First-line immunotherapy for KRAS-Mutant advanced NSCLC: A Systematic Review and Network Meta-analysis|Resistance mechanisms and efficacy of first-line alectinib in patients (pts) with ALK+ non-small cell lung cancer|Lazertinib vs Osimertinib in 1L EGFR-mutant Advanced NSCLC: Exploratory Analysis from MARIPOSA study|Zongertinib in patients with HER2-mutant NSCLC: updated analysis of Beamion LUNG-1|FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in Advanced NSCLC with EGFR PACC Mutations

O7

Oral Session 7
Lung Cancer / Thoracic Cancer 1

ToshiMenju{MENJUTOSHI}|TadashiOkamoto{OKAMOTOTADASHI}|YoshimasaShiraishi{SHIRAISHIYOSHIMASA}|TakanoriEnomoto{ENOMOTOTAKANORI}|ShoichiroYamamoto{YAMAMOTOSHOICHIRO}|TakahiroYoshizawa{YOSHIZAWATAKAHIRO}____MakotoMaemondo{MAEMONDOMAKOTO}|ToshiakiTakahashi{TAKAHASHITOSHIAKI}____KemototsuKemototsu{KEMOTOTSUKEMOTOTSU}|SeijiNiho{NIHOSEIJI}|MasahiroTsuboi{TSUBOIMASAHIRO}|MasashiWakabayashi{WAKABAYASHIMASASHI}|GenichiroIshii{ISHIIGENICHIRO}|HajimeAsahina{ASAHINAHAJIME}|KanaWatanabe{WATANABEKANA}|MoriyukiKiyoshima{KIYOSHIMAMORIYUKI}|TakekazuIwata{IWATATAKEKAZU}|YukikoNakamura{NAKAMURAYUKIKO}|KatsuhikoNaoki{NAOKIKATSUHIKO}|ToyufumiFengshiChen-Yoshikawa{FENGSHICHEN-YOSHIKAWATOYUFUMI}|KazumiNishino{NISHINOKAZUMI}|WataruNishino{NISHINOWATARU}|ToshihideYokoyama{YOKOYAMATOSHIHIDE}|NorikoMitome{MITOMENORIKO}|HisaoAsamura{ASAMURAHISAO}|YuiciroOhe{OHEYUICIRO}|Shun-IchiWatanabe{WATANABESHUN-ICHI}|KenYamamoto{YAMAMOTOKEN}|AkitoHata{HATAAKITO}|YutaYamanaka{YAMANAKAYUTA}|ToshiyukiSumi{SUMITOSHIYUKI}|MotohiroTamiya{TAMIYAMOTOHIRO}|YukoOya{OYAYUKO}|YukiSato{SATOYUKI}|KosukeHamai{HAMAIKOSUKE}|KatsuhikoIwasaki{IWASAKIKATSUHIKO}|TatsuhiroUenishi{UENISHITATSUHIRO}|KokuboKinya{KINYAKOKUBO}|AtaruIgarashi{IGARASHIATARU}|TakayukiShimose{SHIMOSETAKAYUKI}|YukoTsuchiya{TSUCHIYAYUKO}|HidenobuIshii{ISHIIHIDENOBU}|KeikoMizuno{MIZUNOKEIKO}|YukihiroToi{TOIYUKIHIRO}|HarukoDaga{DAGAHARUKO}|KentaroIto{ITOKENTARO}|ShinjiIyama{IYAMASHINJI}|HirokazuTaniguchi{TANIGUCHIHIROKAZU}|RyotaroMorinaga{MORINAGARYOTARO}|TaishiHarada{HARADATAISHI}|IsamuOkamoto{OKAMOTOISAMU}|YuTakahara{TAKAHARAYU}|YukaFujita{FUJITAYUKA}|NanamiKida{KIDANANAMI}|MarikoOkamoto{OKAMOTOMARIKO}|DaisukeHazama{HAZAMADAISUKE}|NaokoKatsurada{KATSURADANAOKO}|MasatsuguYamamoto{YAMAMOTOMASATSUGU}|NaoeJimbo{JIMBONAOE}|MotokoTachihara{TACHIHARAMOTOKO}|YuichiroOhe{OHEYUICHIRO}|BaohuiHan{HANBAOHUI}|MakotoNishio{NISHIOMAKOTO}|SatoshiWatanabe{WATANABESATOSHI}|XiubaoRen{RENXIUBAO}|ShujiMurakami{MURAKAMISHUJI}|NongYang{YANGNONG}|GaofengLi{LIGAOFENG}|NobuyukiKatakami{KATAKAMINOBUYUKI}|XianlingLiu{LIUXIANLING}|YukiNakagawa{NAKAGAWAYUKI}|MasayaSasaki{SASAKIMASAYA}|ToshihiroNanki{NANKITOSHIHIRO}|ChunyuQian{QIANCHUNYU}|NobuyukiYamamoto{YAMAMOTONOBUYUKI}|YuSaida{SAIDAYU}|TetsuhikoAsao{ASAOTETSUHIKO}|AkiraKisohara{KISOHARAAKIRA}|RyoMorita{MORITARYO}|TakuNakagawa{NAKAGAWATAKU}|YokoTsukita{TSUKITAYOKO}|NaokiFuruya{FURUYANAOKI}|TaichiMiyawaki{MIYAWAKITAICHI}|NobuhisaIshikawa{ISHIKAWANOBUHISA}|TadaakiYamada{YAMADATADAAKI}|TakashiKasai{KASAITAKASHI}|TakahiroTanaka{TANAKATAKAHIRO}|ToshiakiKikuchi{KIKUCHITOSHIAKI}|KunihikoKobayashi{KOBAYASHIKUNIHIKO}|MakotoMaemondo{MAEMONDOMAKOTO}____Mini Oral Session 8Lung Cancer / Thoracic Cancer 1 (Small Cell Lung Cancer 1）____Final overall survival analysis of JCOG1205/1206; phase III study of IP versus EP for resected HGNEC of the lung|Cost-effectiveness of atezolizumab (ATZ) vs. durvalumab (DUR) in elderly ED-SCLC patients: RWD on first-line Chemo-ICIs|Phase II Study of Platinum plus Etoposide with Durvalumab for Extensive-Stage SCLC with Untreated Brain Metastases|Current Status of First-Line Treatment for Extensive-Stage Small Cell Lung Cancer and Review of Long-Term Responders|Third OS interim analysis from BEAT-SC: Addition of bevacizumab to atezolizumab & chemotherapy in patients with ES-SCLC|Durvalumab plus carboplatin and etoposide for extensive-stage small-cell lung cancer patients with a poor PS (NEJ045A)

MO8

Mini Oral Session 8
Lung Cancer / Thoracic Cancer 1 (Small Cell Lung Cancer 1）

YukiAkazawa{AKAZAWAYUKI}|AfshinDowlati{DOWLATIAFSHIN}|HirokiIzumi{IZUMIHIROKI}|KadoakiOhashi{OHASHIKADOAKI}|ShunichiSugawara{SUGAWARASHUNICHI}|－|ToshiyaFujisaki{FUJISAKITOSHIYA}____NaokiNishimura{NISHIMURANAOKI}|YutakaFujiwara{FUJIWARAYUTAKA}____YasuhiroMihashi{MIHASHIYASUHIRO}|RyosukeNishijima{NISHIJIMARYOSUKE}|YukihiroYano{YANOYUKIHIRO}|MasahideMori{MORIMASAHIDE}|JunjiUchida{UCHIDAJUNJI}|AnneCChiang{CHIANGANNEC}|AndrésCervantes{CERVANTESANDRÉS}|SunilBabu{BABUSUNIL}|ErikaHamilton{HAMILTONERIKA}|ShuFenWong{WONGSHUFEN}|AndreaTazbirkova{TAZBIRKOVAANDREA}|IvanaGabrielaSullivan{SULLIVANIVANAGABRIELA}|CédricVanMarcke{MARCKECÉDRICVAN}|AntoineItaliano{ITALIANOANTOINE}|JilpaPatel{PATELJILPA}|SabeenMekan{MEKANSABEEN}|TiaWu{WUTIA}|SaiamaNWaqar{WAQARSAIAMAN}|JacobSands{SANDSJACOB}|ByoungChulCho{CHOBYOUNGCHUL}|Myung-JuAhn{AHNMYUNG-JU}|MartinReck{RECKMARTIN}|JeanBustamanteAlvarez{ALVAREZJEANBUSTAMANTE}|Horst-DieterHummel{HUMMELHORST-DIETER}|HiroakiAkamatsu{AKAMATSUHIROAKI}|MelissaL.Johnson{JOHNSONMELISSAL.}|EnriquetaFelip{FELIPENRIQUETA}|SabinHandzhiev{HANDZHIEVSABIN}|IppokratisKorantzis{KORANTZISIPPOKRATIS}|Anne-MarieDingemans{DINGEMANSANNE-MARIE}|FionaBlackhall{BLACKHALLFIONA}|TaofeekK.Owonikoko{OWONIKOKOTAOFEEKK.}|JürgenWolf{WOLFJÜRGEN}|SureshS.Ramalingam{RAMALINGAMSURESHS.}|HosseinBorghaei{BORGHAEIHOSSEIN}|ShuangHuang{HUANGSHUANG}|LuisPaz-Ares{PAZ-ARESLUIS}|HirokiIzumi{IZUMIHIROKI}|Jong-SeokLee{LEEJONG-SEOK}|Ji-YounHan{HANJI-YOUN}|Chi-LuChiang{CHIANGCHI-LU}|AliHamidi{HAMIDIALI}|SujoyMukherjee{MUKHERJEESUJOY}|KristaLinXu{XUKRISTALIN}|E.Kalinka{KALINKAE.}|I.Bahce{BAHCEI.}|A.Navarro{NAVARROA.}|N.Ready{READYN.}|Q.s-CChu{CHUQ.S-C}|A.Sibille{SIBILLEA.}|M.ProvencioPulla{PROVENCIOPULLAM.}|M.l.Johnson{JOHNSONM.L.}|T.j.n.Hiltermann{HILTERMANNT.J.N.}|T-E.Ciuleanu{CIULEANUT-E.}|R.Dziadziuszko{DZIADZIUSZKOR.}|A.Santo{SANTOA.}|Y.Zhang{ZHANGY.}|Y.Liu{LIUY.}|R.Sarmiento{SARMIENTOR.}|S.Tannenbaum-Dvir{TANNENBAUM-DVIRS.}|L.Ojalvo{OJALVOL.}|J.Wu{WUJ.}|K.j.O'byrne{O'BYRNEK.J.}|HirotsuguKenmotsu{KENMOTSUHIROTSUGU}|SuguruMatsuda{MATSUDASUGURU}|MeikoMorita{MORITAMEIKO}|MotokiSekikawa{SEKIKAWAMOTOKI}|HiroakiKodama{KODAMAHIROAKI}|MichitoshiYabe{YABEMICHITOSHI}|KeitaMiura{MIURAKEITA}|NobuakiMamesaya{MAMESAYANOBUAKI}|HarukiKobayashi{KOBAYASHIHARUKI}|RyoKo{KORYO}|KazushigeWakuda{WAKUDAKAZUSHIGE}|AkiraOno{ONOAKIRA}|TateakiNaito{NAITOTATEAKI}|HaruyasuMurakami{MURAKAMIHARUYASU}|HideyukiHarada{HARADAHIDEYUKI}|ToshiakiTakahashi{TAKAHASHITOSHIAKI}____Mini Oral Session 9Lung Cancer / Thoracic Cancer 2 (Small Cell Lung Cancer 2）____Chemotherapy Sensitivity for Recurrent Small-cell Lung Cancer Based on Chemotherapy-Free Interval and Treatment Regimens|Sacituzumab Govitecan (SG) as Second-Line Treatment in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC)|Tarlatamab Sustained Clinical Benefit and Safety in Previously Treated SCLC: DeLLphi-301 Phase 2 Extended Follow-up|Tarlatamab in previously treated SCLC: Subgroup analysis of patients from the Asia region (Phase 2 DeLLphi-301 study)|Interim analysis of a randomized study of 1L BMS-986012 (anti-fucosyl-GM-1) with Chemotherapy and nivolumab in ES-SCLC|Withdrawn|Eligibility for durvalumab treatment after concurrent chemoradiotherapy in limited-stage small cell lung cancer

MO9

Mini Oral Session 9
Lung Cancer / Thoracic Cancer 2 (Small Cell Lung Cancer 2）

IchiroKinoshita{KINOSHITAICHIRO}|YoshimichiHaruna{HARUNAYOSHIMICHI}|RyoYoshimaru{YOSHIMARURYO}|YusukeKajimoto{KAJIMOTOYUSUKE}____NoriyukiKatsumata{KATSUMATANORIYUKI}|KohichiTakada{TAKADAKOHICHI}|NishimoriHisakazu{HISAKAZUNISHIMORI}|YukiShinno{SHINNOYUKI}____ManabuMuto{MUTOMANABU}|SatoshiNishiwaki{NISHIWAKISATOSHI}|NaohiroNishida{NISHIDANAOHIRO}|MasahiroTabata{TABATAMASAHIRO}|NoboruYamamoto{YAMAMOTONOBORU}|YusukeSato{SATOYUSUKE}|EishiBaba{BABAEISHI}|HiroshiNishihara{NISHIHARAHIROSHI}|ToruMukohara{MUKOHARATORU}|HidekazuShirota{SHIROTAHIDEKAZU}|NobuakiMamesaya{MAMESAYANOBUAKI}|HonokaUeno{UENOHONOKA}|TetsuyaTakao{TAKAOTETSUYA}|TakayukiYakushijin{YAKUSHIJINTAKAYUKI}|HirotakaNakamura{NAKAMURAHIROTAKA}|Song-GiChi{CHISONG-GI}|Mei-GuoYon{YONMEI-GUO}|YousukMinami{MINAMIYOUSUK}|JunichiroYuda{YUDAJUNICHIRO}|AkihitoNagata{NAGATAAKIHITO}|ShinichiNomura{NOMURASHINICHI}____Oral Session 8Cross-sectional Program____Phase II trial of nivolumab in advanced solid tumors based on genomic profiling: BELIEVE trial (NCCH1901) subcohort|Peripheral CD4+T cell subsets as pretreatment biomarkers for predicting antitumor response to anti-PD-1/PD-L1 therapy|Retrospective Study on the Impact of Hematological irAE on Cancer Treatment After Use of Immune Checkpoint Inhibitors|Comparison between Japanese and Overall Data: Meta-analysis from Phase 3 Trials of Immune Checkpoint Inhibitor

O8

Oral Session 8
Cross-sectional Program

KojiMatsumoto{MATSUMOTOKOJI}|HirokazuOgino{OGINOHIROKAZU}|NoboruYamamoto{YAMAMOTONOBORU}|TomohiroNakayama{NAKAYAMATOMOHIRO}|ShiroKimbara{KIMBARASHIRO}|JunichiMatsubara{MATSUBARAJUNICHI}____YoshitsuguHorio{HORIOYOSHITSUGU}|TakahiroKogawa{KOGAWATAKAHIRO}____HiroakiKanemura{KANEMURAHIROAKI}|JunkoTanizaki{TANIZAKIJUNKO}|ToshikiMasuishi{MASUISHITOSHIKI}|TaichiIsobe{ISOBETAICHI}|HiroakiKodama{KODAMAHIROAKI}|ToshioShimizu{SHIMIZUTOSHIO}|YuSunakawa{SUNAKAWAYU}|YasutakaChiba{CHIBAYASUTAKA}|NobuyukiYamamoto{YAMAMOTONOBUYUKI}|KazuhikoNakagawa{NAKAGAWAKAZUHIKO}|HidetoshiHayashi{HAYASHIHIDETOSHI}|AtsuroSaijo{SAIJOATSURO}|YasuhikoNishioka{NISHIOKAYASUHIKO}|NicholasAButowski{BUTOWSKINICHOLASA}|SusanMChang{CHANGSUSANM}|MitchelSBerger{BERGERMITCHELS}|HidehoOkada{OKADAHIDEHO}|GauravBajaj{BAJAJGAURAV}|PeterHertel{HERTELPETER}|HomerC.AdamsIii{ADAMSIIIHOMERC.}|AmiTakahashi{TAKAHASHIAMI}|EdwardRamirezGanoza{RAMIREZGANOZAEDWARD}|YasutoshiKuboki{KUBOKIYASUTOSHI}|TakayukiTakahama{TAKAHAMATAKAYUKI}|NaokiShiraishi{SHIRAISHINAOKI}|HisatoKawakami{KAWAKAMIHISATO}|KimioYonesaka{YONESAKAKIMIO}|NaoeJimbo{JIMBONAOE}|NaomiKiyota{KIYOTANAOMI}|HiroakiHanafusa{HANAFUSAHIROAKI}|KeikoTanaka{TANAKAKEIKO}|YukiSawada{SAWADAYUKI}|NorikoNoguchi{NOGUCHINORIKO}|HisayukiMatsumoto{MATSUMOTOHISAYUKI}|GenKanemori{KANEMORIGEN}|NatsukoMurase{MURASENATSUKO}|YutaroUsui{USUIYUTARO}|TakuNose{NOSETAKU}|KeikoGoto{GOTOKEIKO}|TaijiKoyama{KOYAMATAIJI}|YoshiakiNagatani{NAGATANIYOSHIAKI}|YoheiFunakoshi{FUNAKOSHIYOHEI}|HironobuMinami{MINAMIHIRONOBU}|KumiMukai{MUKAIKUMI}|ManabuMuto{MUTOMANABU}____Mini Oral Session 10Cross-sectional Program 1____Phase Ia/Ib trial on the safety and efficacy of mobocertinib and T-DM1 for patients with HER2-mutant solid tumors|Multi-peptide vaccine plus agonistic anti-CD27 antibody induces peripheral effector memory T-cells in low grade glioma|Acasunlimab Alone or in Combination With Pembrolizumab in Japanese Patients With Advanced or Metastatic Solid Tumors|Evaluation of immune checkpoint inhibitor efficacy for solid tumors with CD274 (PD-L1 gene) amplification|Diagnostic Impact of Comprehensive Gene Profiling in Patients with Pathologically Diagnosed Advanced Solid Malignancies|The nationwide survey in Japanese public opinion about off-label drug use recommended by comprehensive genomic profiling

MO10

Mini Oral Session 10
Cross-sectional Program 1

HansMichaelGGunawan{GUNAWANHANSMICHAELG}|JoycelynJLee{LEEJOYCELYNJ}|YewanLim{LIMYEWAN}|YukiMiyai{MIYAIYUKI}|TakafumiMie{MIETAKAFUMI}|YuriMaegawa{MAEGAWAYURI}____HiroshiMiyamoto{MIYAMOTOHIROSHI}|MasaruFukahori{FUKAHORIMASARU}____SherlyBudiman{BUDIMANSHERLY}|JenniferEGunawan{GUNAWANJENNIFERE}|AmosIChandra{CHANDRAAMOSI}|UmairahBAbdulMajeed{ABDULMAJEEDUMAIRAHB}|ShiQiLim{LIMSHIQI}|KennedyYNg{NGKENNEDYY}|DavidWTai{TAIDAVIDW}|SuatYingLee{LEESUATYING}|AzzahraMaheswariNoersjamjah{NOERSJAMJAHAZZAHRAMAHESWARI}|AmosImmanuelChandra{CHANDRAAMOSIMMANUEL}|AndreeKurniawan{KURNIAWANANDREE}|OsamuMaeda{MAEDAOSAMU}|MegumiInada-Inoue{INADA-INOUEMEGUMI}|HidekiTakami{TAKAMIHIDEKI}|TakuyaIshikawa{ISHIKAWATAKUYA}|JunpeiYamaguchi{YAMAGUCHIJUNPEI}|HirokiKawashima{KAWASHIMAHIROKI}|TomokiEbata{EBATATOMOKI}|YuichiAndo{ANDOYUICHI}|MasatoOzaka{OZAKAMASATO}|YoichiroSato{SATOYOICHIRO}|TatsukiHirai{HIRAITATSUKI}|YuriMaegawa{MAEGAWAYURI}|TakaakiFurukawa{FURUKAWATAKAAKI}|TakeshiOkamoto{OKAMOTOTAKESHI}|TsuyoshiTakeda{TAKEDATSUYOSHI}|TakashiSasaki{SASAKITAKASHI}|NaokiSasahira{SASAHIRANAOKI}|TakahiroIshitsuka{ISHITSUKATAKAHIRO}|YukariSuzuki{SUZUKIYUKARI}|TakafumiMie{MIETAKAFUMI}____Mini Oral Session 11Hepatobiliary / Pancreatic Cancer 1 (Pancreatic Cancer 1)____Whipple vs Pylorus-Preserving Pancreaticoduodenectomy for Pancreatic Tumors: A Meta-Analysis of Surgical Techniques|Real-world utilisation of somatic tumour profiling in patients with advanced pancreas cancer: a single-centre study|FOLFIRINOX vs FOLFIRINOX-surgery efficacy in Borderline Resectable and Locally Advanced Pancreatic Cancer: Meta-Analysis|Association of Cholinergic Symptoms and Treatment Outcomes in Pancreatic Cancer Patients Receiving FOLFIRINOX Therapy|Post progression survival of modified FOLFIRINOX and gemcitabine with nab-paclitaxel for unresectable pancreatic cancer|The Impact of KRAS Mutations on Prognosis in Metastatic or Recurrent Pancreatic Cancer

MO11

Mini Oral Session 11
Hepatobiliary / Pancreatic Cancer 1 (Pancreatic Cancer 1)

ToruOtsuru{OTSURUTORU}|YusukeKawanaka{KAWANAKAYUSUKE}|KumikoUmemoto{UMEMOTOKUMIKO}|AishwaryaSingh{SINGHAISHWARYA}|RifaldyFajar{FAJARRIFALDY}|KazuyoshiNoda{NODAKAZUYOSHI}____TakujiOkusaka{OKUSAKATAKUJI}|TaroShibuki{SHIBUKITARO}____YoshinoriOhno{OHNOYOSHINORI}|AkinoriAsagi{ASAGIAKINORI}|KaoriHino{HINOKAORI}|AzusaKomori{KOMORIAZUSA}|ChihiroSakaguchi{SAKAGUCHICHIHIRO}|TakeshiKajiwara{KAJIWARATAKESHI}|TomohiroNishina{NISHINATOMOHIRO}|IchinosukeHyodo{HYODOICHINOSUKE}|ChiakiInagaki{INAGAKICHIAKI}|MasakiOkura{OKURAMASAKI}|SeiichiroMitani{MITANISEIICHIRO}|TakayukiTakahama{TAKAHAMATAKAYUKI}|KimioYonesaka{YONESAKAKIMIO}|KazuhikoNakagawa{NAKAGAWAKAZUHIKO}|HisatoKawakami{KAWAKAMIHISATO}|HidetoshiHayashi{HAYASHIHIDETOSHI}|YasutakaChiba{CHIBAYASUTAKA}|KazunariNakahara{NAKAHARAKAZUNARI}|NobuyukiOhike{OHIKENOBUYUKI}|YusukeSatta{SATTAYUSUKE}|AkihiroSekine{SEKINEAKIHIRO}|YosukeIgarashi{IGARASHIYOSUKE}|YusukeNagata{NAGATAYUSUKE}|YoheiKubota{KUBOTAYOHEI}|HiroyukiTakeda{TAKEDAHIROYUKI}|YoshikiHorie{HORIEYOSHIKI}|HiroyukiArai{ARAIHIROYUKI}|NaokiIzawa{IZAWANAOKI}|HayatoHiraki{HIRAKIHAYATO}|TomokoNorose{NOROSETOMOKO}|JunkiKoike{KOIKEJUNKI}|RyoMatoba{MATOBARYO}|SatoshiNishizuka{NISHIZUKASATOSHI}|KeisukeTateishi{TATEISHIKEISUKE}|YuSunakawa{SUNAKAWAYU}|BhudevCDas{BhudevCDas}|ManojGarg{GARGMANOJ}|YasushiSato{SATOYASUSHI}|MasanoriTakehara{TAKEHARAMASANORI}|YasuyukiOkada{OKADAYASUYUKI}|YasuhiroMitsui{MITSUIYASUHIRO}|YutakaKawano{KAWANOYUTAKA}|KoichiOkamoto{OKAMOTOKOICHI}|HiroshiMiyamoto{MIYAMOTOHIROSHI}|TetsujiTakayama{TAKAYAMATETSUJI}____Mini Oral Session 12Hepatobiliary / Pancreatic Cancer 2（Pancreatic Cancer 2）____Tumor tissue and liquid comprehensive genomic profiling test for advanced pancreatic cancer in an institution|The Prevalence and Prognostic Impact of Co-existing Gene Alterations in PDAC with or without HRR Gene Alteration|The clinical validity of digital PCR for the identification of KRAS mutation by cytology specimens in pancreatic cancer|Deciphering the oncogenic potential of SOX21-AS1 lncRNA in tumorigenesis of pancreatic ductal adenocarcinoma|Machine Learning-Driven Identification of CAF Subtypes via Exosomal RNA Modifications in Immune-Exclusion Tumors|Mir-199a-3p in the exosome secreted from cancer-associated adipocytes promotes pancreatic cancer progression

MO12

Mini Oral Session 12
Hepatobiliary / Pancreatic Cancer 2（Pancreatic Cancer 2）

MasatoOzaka{OZAKAMASATO}|AtsushiNaganuma{NAGANUMAATSUSHI}|ZevA.Wainberg{WAINBERGZEV}|SakiTanaka{TANAKASAKI}|－____MasashiKanai{KANAIMASASHI}|KelleyRobinKate{ROBINKATEKELLEY}|KawamotoYasuyuki{YASUYUKIKAWAMOTO}|TeresaMacarulla{MACARULLATERESA}____RichardS.Finn{FINNRICHARDS.}|ChanghoonYoo{YOOCHANGHOON}|ZhenggangRen{RENZHENGGANG}|RobinKateKelley{KELLEYROBINKATE}|StephenLamChan{CHANSTEPHENLAM}|JulienEdeline{EDELINEJULIEN}|HeinzJosefKlümpen{KLÜMPENHEINZJOSEF}|ThomasYau{YAUTHOMAS}|ChrisVerslype{VERSLYPECHRIS}|MohamedBouattour{BOUATTOURMOHAMED}|JoonOhPark{PARKJOONOH}|ArndtVogel{VOGELARNDT}|JuanW.Valle{VALLEJUANW.}|ShukuiQin{QINSHUKUI}|JunjiFuruse{FURUSEJUNJI}|LiisStarkopf{STARKOPFLIIS}|UshaMalhotra{MALHOTRAUSHA}|AbbyB.Siegel{SIEGELABBYB.}|MakotoUeno{UENOMAKOTO}|SatoruKakizaki{KAKIZAKISATORU}|AtsushiHiraoka{HIRAOKAATSUSHI}|ToshifumiTada{TADATOSHIFUMI}|TakeshiHatanaka{HATANAKATAKESHI}|KazunariTanaka{TANAKAKAZUNARI}|KunihikoTsuji{TSUJIKUNIHIKO}|HidenoriToyoda{TOYODAHIDENORI}|KazuhiroNouso{NOUSOKAZUHIRO}|ToruIshikawa{ISHIKAWATORU}|MasanoriAtsukawa{ATSUKAWAMASANORI}|EiItobayashi{ITOBAYASHIEI}|KoichiTakaguchi{TAKAGUCHIKOICHI}|JojiTani{TANIJOJI}|KazutoTajiri{TAJIRIKAZUTO}|HidekatsuKuroda{KURODAHIDEKATSU}|YoichiHiasa{HIASAYOICHI}|MasatoshiKudo{KUDOMASATOSHI}|TakashiKumada{KUMADATAKASHI}|JasonLink{LINKJASON}|DavidDawson{DAWSONDAVID}|LeeRosen{ROSENLEE}|StephenKim{KIMSTEPHEN}|MarkGirgis{GIRGISMARK}|JonathanKing{KINGJONATHAN}|SaeedSadeghi{SADEGHISAEED}|OlgaOlevsky{OLEVSKYOLGA}|DeborahWong{WONGDEBORAH}|HarsimranMultani{MULTANIHARSIMRAN}|JennaDavis{DAVISJENNA}|LisYonemoto{YONEMOTOLIS}|AnnMarieSiney{SINEYANNMARIE}|ChristineKivork{KIVORKCHRISTINE}|Chi-HongTseng{TSENGCHI-HONG}|JoeHines{HINESJOE}|TimDonahue{DONAHUETIM}|RyojiTakada{TAKADARYOJI}|KenjiIkezawa{IKEZAWAKENJI}|KazuyoshiOhkawa{OHKAWAKAZUYOSHI}|SayakaNakamura{NAKAMURASAYAKA}|SatoshiNishiuma{NISHIUMASATOSHI}|KeisukeNozaki{NOZAKIKEISUKE}|YukioKadokawa{KADOKAWAYUKIO}|MariTakagi{TAKAGIMARI}____Oral Session 9Hepatobiliary / Pancreatic Cancer____Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: 3-year follow-up of KEYNOTE-966|Time-of-day patterns of Atezolizumab and Bevacizumab and Outcomes in Patients with Unresectable Hepatocellular Carcinoma|A Pilot Clinical Trial of Modified FOLFIRINOX plus Nivolumab in Borderline Resectable Pancreas Cancer|A study on the time to treatment failure of nanoliposomal irinotecan+5-FU/l-LV for unresectable pancreatic cancer|Withdrawn

O9

Oral Session 9
Hepatobiliary / Pancreatic Cancer

HarshGoel{GOELHARSH}|ZiyanZhang{ZHANGZIYAN}|SatoshiSuzuki{SUZUKISATOSHI}|RyutaroOnaga{ONAGARYUTARO}|NaomiKiyota{KIYOTANAOMI}|JunTaguchi{TAGUCHIJUN}____TakenoriOgawa{OGAWATAKENORI}|TakaoFujisawa{FUJISAWATAKAO}____PranayTanwar{TANWARPRANAY}|AbhimanyuKumarJha{JHAABHIMANYUKUMAR}|TomoyaYokota{YOKOTATOMOYA}|AkifumiNotsu{NOTSUAKIFUMI}|KunihiroFushiki{FUSHIKIKUNIHIRO}|KotoeOshima{OSHIMAKOTOE}|AkihiroOhba{OHBAAKIHIRO}|TakeshiKawakami{KAWAKAMITAKESHI}|TakahiroTsushima{TSUSHIMATAKAHIRO}|SatoshiHamauchi{HAMAUCHISATOSHI}|HirofumiYasui{YASUIHIROFUMI}|YusukeOnozawa{ONOZAWAYUSUKE}|TakashiMukaigawa{MUKAIGAWATAKASHI}|YasuhiroTsubosa{TSUBOSAYASUHIRO}|HirofumiOgawa{OGAWAHIROFUMI}|TsuyoshiOnoe{ONOETSUYOSHI}|KentaroYamazaki{YAMAZAKIKENTARO}|TomohiroEnokida{ENOKIDATOMOHIRO}|ShingoSakashita{SAKASHITASHINGO}|SusumuOkano{OKANOSUSUMU}|TakaoFujisawa{FUJISAWATAKAO}|NobukazuTanaka{TANAKANOBUKAZU}|YutaHoshi{HOSHIYUTA}|TakumaKishida{KISHIDATAKUMA}|RyoKuboki{KUBOKIRYO}|MakotoTahara{TAHARAMAKOTO}|HirooImai{IMAIHIROO}|ShunjiTakahashi{TAKAHASHISHUNJI}|AkihiroNishiyama{NISHIYAMAAKIHIRO}|ShingoTamura{TAMURASHINGO}|YasushiShimizu{SHIMIZUYASUSHI}|ShigenoriKadowaki{KADOWAKISHIGENORI}|Ken-IchiIto{ITOKEN-ICHI}|MasahiroToyoshima{TOYOSHIMAMASAHIRO}|YoshinoriHirashima{HIRASHIMAYOSHINORI}|ShinjiUeno{UENOSHINJI}|SotaOgata{OGATASOTA}|IwaoSugitani{SUGITANIIWAO}|AkihikoShiiya{SHIIYAAKIHIKO}|RikaMoku{MOKURIKA}|ShinAriga{ARIGASHIN}|TomohiroGoda{GODATOMOHIRO}|TakuroNoguchi{NOGUCHITAKURO}|SatoshiTakeuchi{TAKEUCHISATOSHI}|IchiroKinoshita{KINOSHITAICHIRO}____Mini Oral Session 13Head and Neck Cancer 1 (Head and Neck Cancer 1, Thyroid Cancer, Salivary Gland Cancer)____Genetic Alteration, RNA expression, and DNA Methylation profiling of LATS1 gene in Head-Neck Squamous Cell Carcinoma|Association of Daily Diet and Incidence of Head and Neck Cancer: A Prospective Cohort Study of UK Biobank Participants|Clinical outcomes of patients with locally advanced synchronous head and neck and esophageal cancer|Concordance of BRAF V600E mutation status between immunohistochemistry and genomic testing in thyroid cancer|Health-related Quality of Life in a Phase II Study of Encorafenib Plus Binimetinib for BRAF V600 Mutated Thyroid Cancer|Retrospective Analysis of Taxane combination Chemotherapy for Recurrent or Metastatic salivary gland carcinoma

MO13

Mini Oral Session 13
Head and Neck Cancer 1 (Head and Neck Cancer 1, Thyroid Cancer, Salivary Gland Cancer)

DanniCheng{CHENGDANNI}|LanFeng{FENGLAN}|HishamMehanna{MEHANNAHISHAM}|AhmadKAbou-Foul{ABOU-FOULAHMADK}|ThunLeewiboonsilp{LEEWIBOONSILPTHUN}|KenSaijo{SAIJOKEN}____HishamMehanna{MEHANNAHISHAM}|AriNishimura{NISHIMURAARI}____YuZhao{ZHAOYU}|JianjunRen{RENJIANJUN}|Abou-FoulKAhmad{AHMADABOU-FOULK}|HensonChristina{CHRISTINAHENSON}|KristunasCaroline{CAROLINEKRISTUNAS}|NankivellCPaul{PAULNANKIVELLC}|LeemansC.René{C.RENÉLEEMANS}|VanDenBrekelWmMichiel{MICHIELVANDENBREKELWM}|VonBuchwaldChristian{CHRISTIANVONBUCHWALD}|LydiattM.William{WILLIAMLYDIATTM.}|GuptaVishal{VISHALGUPTA}|BranstetterF.Barton{BARTONBRANSTETTERF.}|KlussmannJensPeter{JENSPETERKLUSSMANN}|WollenbergBarbara{BARBARAWOLLENBERG}|BroglieA.Martina{MARTINABROGLIEA.}|PrestwichRobin{ROBINPRESTWICH}|MirghaniHaitham{HAITHAMMIRGHANI}|OlivaMarc{MARCOLIVA}|NairSudhir{SUDHIRNAIR}|KrishnanSuren{SURENKRISHNAN}|YomSSue{SUEYOMS}|ChernockD.Rebecca{REBECCACHERNOCKD.}|HuangShaoHui{SHAOHUIHUANG}|McdowellLachlan{LACHLANMCDOWELL}|O'sullivanBrian{BRIANO'SULLIVAN}|Perez-OrdonezBayardo{BAYARDOPEREZ-ORDONEZ}|RobinsonMax{MAXROBINSON}|MehannaHisham{HISHAMMEHANNA}|ChuleeponJianpinijnan{JIANPINIJNANCHULEEPON}|PoompisPattaranutaporn{PATTARANUTAPORNPOOMPIS}|NintitaSripaiboonkijThokanit{SRIPAIBOONKIJTHOKANITNINTITA}|NuttapongNgamphaiboon{NGAMPHAIBOONNUTTAPONG}|HirooImai{IMAIHIROO}|TomoakiShirakawa{SHIRAKAWATOMOAKI}|RyoSaito{SAITORYO}|ShioriIshikawa{ISHIKAWASHIORI}|RyunosukeNumakura{NUMAKURARYUNOSUKE}|YuyaYoshida{YOSHIDAYUYA}|ShoUmegaki{UMEGAKISHO}|SakuraTaniguchi{TANIGUCHISAKURA}|YukiKasahara{KASAHARAYUKI}|KotaOuchi{OUCHIKOTA}|KeigoKomine{KOMINEKEIGO}|HidekazuShirota{SHIROTAHIDEKAZU}|MasanobuTakahashi{TAKAHASHIMASANOBU}|ChikashiIshioka{ISHIOKACHIKASHI}____Mini Oral Session 14Head and Neck Cancer 2 (Head and Neck Cancer 2)____HPV-Status-Dependent Associations of Cholesterol-Lowering Targets with Head and Neck Cancer Survival|Associations between immune-mediated diseases (IMDs) and the risk of HPV-associated oropharyngeal cancer|Accuracy and prognosis of extranodal extension on radiologic imaging in HPV+ oropharyngeal cancer|Standardised definitions and reporting of pENE in head and neck cancer: HNCIG international consensus recommendations|Postoperative RT With or Without Chemotherapy in Locally Advanced HNSCC with Intermediate Risk A Propensity Scores Match|Inverse response between prior pembrolizumab and subsequent cetuximab plus paclitaxel in head and neck cancer patients

MO14

Mini Oral Session 14
Head and Neck Cancer 2 (Head and Neck Cancer 2)

YoshitakaHonma{HONMAYOSHITAKA}|YoshihitoKano{KANOYOSHIHITO}|AhmadKAbou-Foul{ABOU-FOULAHMADK}|SojiToda{TODASOJI}____UlrichKeilholz{KEILHOLZULRICH}|SadamotoZenda{ZENDASADAMOTO}|YasushiShimizu{SHIMIZUYASUSHI}|YoshinoriImamura{IMAMURAYOSHINORI}____IchiroKinoshita{KINOSHITAICHIRO}|SatoshiKano{KANOSATOSHI}|NaomiKiyota{KIYOTANAOMI}|MakotoTahara{TAHARAMAKOTO}|ShunjiTakahashi{TAKAHASHISHUNJI}|YoichiIto{ITOYOICHI}|YoshihiroMatsuno{MATSUNOYOSHIHIRO}|YutakaHatanaka{HATANAKAYUTAKA}|HirotoshiAkita{AKITAHIROTOSHI}|RikaNoji{NOJIRIKA}|TakahiroNaito{NAITOTAKAHIRO}|SadakatsuIkeda{IKEDASADAKATSU}|HiroyukiHarada{HARADAHIROYUKI}|YasuoHamamoto{HAMAMOTOYASUO}|HensonChristina{CHRISTINAHENSON}|GlastonburyChristine{CHRISTINEGLASTONBURY}|HuangShaoHui{SHAOHUIHUANG}|KingD.Ann{ANNKINGD.}|LydiattM.William{WILLIAMLYDIATTM.}|McdowellLachlan{LACHLANMCDOWELL}|NagelschneiderA.Alex{ALEXNAGELSCHNEIDERA.}|NankivellCPaul{PAULNANKIVELLC}|O'sullivanBrian{BRIANO'SULLIVAN}|YomSSue{SUEYOMS}|MehannaHisham{HISHAMMEHANNA}|YukihikoHiroshima{HIROSHIMAYUKIHIKO}|MeiKadoya{KADOYAMEI}|ChihiroSuzuki{SUZUKICHIHIRO}|HaruhikoYamazaki{YAMAZAKIHARUHIKO}|KatsuhikoMasudo{MASUDOKATSUHIKO}____Oral Session 10Head and Neck Cancer____Phase II study of trastuzumab deruxtecan for HER2-positive recurrent or metastatic salivary gland cancer (MYTHOS trial)|Clinical Utility of Liquid Biopsy in HNSCC: Insights from the SHIZUKU-HN Study and C-CAT Data|Criteria for the diagnosis of ENE detected on imaging in head and neck cancer: HNCIG international recommendations|Prognostic impact of gene alterations related to PI3K and cell cycle pathways in differentiated thyroid carcinoma

O10

Oral Session 10
Head and Neck Cancer

ShoheiUdagawa{UDAGAWASHOHEI}|YoheiOsaki{OSAKIYOHEI}|YusukeKurioka{KURIOKAYUSUKE}|AyakoMitsuma{MITSUMAAYAKO}|JunjiHiraga{HIRAGAJUNJI}|TerunobuHaruyama{HARUYAMATERUNOBU}____KazuhikoShibata{SHIBATAKAZUHIKO}|FumieFujisawa{FUJISAWAFUMIE}____ShotaFukuoka{FUKUOKASHOTA}|HirokiOsumi{OSUMIHIROKI}|EmikoTange{TANGEEMIKO}|HiroshiNaito{NAITOHIROSHI}|YukariSuzuki{SUZUKIYUKARI}|KoichiroYoshino{YOSHINOKOICHIRO}|MikakoTamba{TAMBAMIKAKO}|KeitaroShimozaki{SHIMOZAKIKEITARO}|TakeruWakatsuki{WAKATSUKITAKERU}|MarikoOgura{OGURAMARIKO}|AkiraOoki{OOKIAKIRA}|KeishoChin{CHINKEISHO}|EijiShinozaki{SHINOZAKIEIJI}|KenseiYamaguchi{YAMAGUCHIKENSEI}|DaisukeTakahari{TAKAHARIDAISUKE}|MisaHirosue{HIROSUEMISA}|HideoSakamoto{SAKAMOTOHIDEO}|TakuyaSatou{SATOUTAKUYA}|HironagaSatake{SATAKEHIRONAGA}|YukiMiyai{MIYAIYUKI}|NaoTorii{TORIINAO}|YukoTkano{TKANOYUKO}|ChiakiKondo{KONDOCHIAKI}|MadokaYanagawa{YANAGAWAMADOKA}|TomoyaShimokata{SHIMOKATATOMOYA}|OsamuMaeda{MAEDAOSAMU}|YokoIshiguro{ISHIGUROYOKO}|SatomiYamada{YAMADASATOMI}|YuichiAndo{ANDOYUICHI}|TomokiFujii{FUJIITOMOKI}|NarukoSuzuki{SUZUKINARUKO}|YasuhikoHarada{HARADAYASUHIKO}____Mini Oral Session 15Patient Advocacy / Survivorship 1 (Treatment)____Association between geriatric assessment and serious adverse events in elderly patients with gastrointestinal cancer|Evaluation of the Usefulness of geriatric assessment for Immune Checkpoint Inhibitor Administration|Assessing the utility of G8 (Geriatric 8) screening tool for cancer patients|Association between G8 Screening and treatment course in older patients with cancer|Fertility and menstrual disorder in female patients of AYA generation with hematological malignancies|Analysis of factors influencing oncologists’ choice of cancer treatment

MO15

Mini Oral Session 15
Patient Advocacy / Survivorship 1 (Treatment)

HirotakaKoyanagi{KOYANAGIHIROTAKA}|HirokiSakuyama{SAKUYAMAHIROKI}|QuyPhamnguyen{PHAMNGUYENQUY}|EvelynYiTingWong{WONGEVELYNYITING}|HidekiKatayama{KATAYAMAHIDEKI}|RikaKizawa{KIZAWARIKA}____KokoroKobayashi{KOBAYASHIKOKORO}____SyoheiTsujino{TSUJINOSYOHEI}|ChigusaSawamura{SAWAMURACHIGUSA}|KaedeShinmura{SHINMURAKAEDE}|KaitoSaito{SAITOKAITO}|TabuGokita{GOKITATABU}|YoriyukiTahara{TAHARAYORIYUKI}|SenaTsukamoto{TSUKAMOTOSENA}|IkuhiroKita{KITAIKUHIRO}|KotoneNomura{NOMURAKOTONE}|AkitsuMurakami{MURAKAMIAKITSU}|YoshihiroOkita{OKITAYOSHIHIRO}|HiroyukiOkuyama{OKUYAMAHIROYUKI}|TakamasaNishiuchi{NISHIUCHITAKAMASA}|AkihitoTsuji{TSUJIAKIHITO}|DanNguyenDuc{NGUYENDUCDAN}|TamLac{LACTAM}|TrangBachThi{BACHTHITRANG}|BinhPhanThanh{PHANTHANHBINH}|BaoHanNguyenHoang{NGUYENHOANGBAOHAN}|HaiPhamThu{PHAMTHUHAI}|BichHopBuiThi{BUITHIBICHHOP}|ThuyDuongNguyenThi{NGUYENTHITHUYDUONG}|NgocHanhNguyenThi{NGUYENTHINGOCHANH}|MinhTamNguyen{NGUYENMINHTAM}|ChauDucNguyenHuu{NGUYENHUUCHAUDUC}|WeiLinGoh{GOHWEILIN}|SriNurQurnianyBinteAbdulLatif{BINTEABDULLATIFSRINURQURNIANY}|NurulshazwaniBteMohdShahrudin{BTEMOHDSHAHRUDINNURULSHAZWANI}|VictoriaWong{WONGVICTORIA}|DanielQuah{QUAHDANIEL}|YungYingTan{TANYUNGYING}|SeleneChan{CHANSELENE}|MohamadFaridBinHarunalRashid{BINHARUNALRASHIDMOHAMADFARID}|EileenYiLingPoon{POONEILEENYILING}|EikiIchihara{ICHIHARAEIKI}|MasahiroTabata{TABATAMASAHIRO}|MeikoNishimura{NISHIMURAMEIKO}|NaoYoshida{YOSHIDANAO}|KiyomiNonogaki{NONOGAKIKIYOMI}|IkukoKamogawa{KAMOGAWAIKUKO}|SayakaKato{KATOSAYAKA}|KeikoHamaguchi{HAMAGUCHIKEIKO}|MakikoOno{ONOMAKIKO}|YosukeAoyama{AOYAMAYOSUKE}|YukinoriOzaki{OZAKIYUKINORI}|KazuyoYoshida{YOSHIDAKAZUYO}|TomomiAbe{ABETOMOMI}|NatsueUehiro{UEHIRONATSUE}|AkemiKataoka{KATAOKAAKEMI}|ToshimiTakano{TAKANOTOSHIMI}|TakayukiUeno{UENOTAKAYUKI}|MasayukiWatanabe{WATANABEMASAYUKI}____Mini Oral Session 16Patient Advocacy / Survivorship 2 (Social Context Surrounding Patients)____Challenges in Predicting Osteoporotic Fracture Risk in Cancer Patients: Insights from Machine Learning Model Analysis|A retrospective study on time toxicity of cancer chemotherapy|Tackling Cancer-Related Misinformation in Vietnam: A Model for Academic-Public Cooperation|Development of a Mobile Application (AYABytes) to Improve Access to Cancer-related Information for AYA Patients|Longitudinal Study on the Understanding and Consideration of Cancer Patients by Employers, Supervisors, and Colleagues|Questionnaire Survey of Healthcare Professionals on the Awareness and Conditions of Young Carers in the Oncology

MO16

Mini Oral Session 16
Patient Advocacy / Survivorship 2 (Social Context Surrounding Patients)

HastiHTolani{TOLANIHASTIH}|EvaCheung{CHEUNGEVA}|DionRavinderTheodeusSubroto{SUBROTODIONRAVINDERTHEODEUS}|AbimanyuSakh{SAKHABIMANYU}|RapeewanSettacomkul{SETTACOMKULRAPEEWAN}____MotooNagane{NAGANEMOTOO}|HiroyukiMomota{MOMOTAHIROYUKI}____ClarissaACendera{CENDERACLARISSAA}|EdwardTanially{TANIALLYEDWARD}|AndreeKurniawan{KURNIAWANANDREE}|IanHuang{HUANGIAN}|AngelaGiselvania{GISELVANIAANGELA}|EllieChu{CHUELLIE}|AlbertLi{LIALBERT}|LarryLam{LAMLARRY}|RickyWu{WURICKY}|YewanLim{LIMYEWAN}|NatashaKarlinaLaw{LAWNATASHAKARLINA}|DevinaRaveliaTiffanySubroto{SUBROTODEVINARAVELIATIFFANY}|NicolasSachio{SACHIONICOLAS}|AmosImmanuelChandra{CHANDRAAMOSIMMANUEL}|AyskaNooranantaZamzami{ZAMZAMIAYSKANOORANANTA}|ZerlurikaPalomaNursari{NURSARIZERLURIKAPALOMA}|RatchanonSukprasert{SUKPRASERTRATCHANON}|RyanC.Harliman{HARLIMANRYANC.}|YukihiroItoh{ITOHYUKIHIRO}|TakayoshiSuzuki{SUZUKITAKAYOSHI}|JirananChotitumnavee{CHOTITUMNAVEEJIRANAN}____Mini Oral Session 17Brain Tumor____Cognitive decline in pediatric brain tumor survivors due to radiotherapy: a double-edged sword|AI Model in Glioblastoma characterization: A novel approach to differentiate necrosis, vascular proliferation and tumour|Comparative Efficacy of Lomustine-Temozolomide Combination Therapy vs Other Regimen in Glioblastoma: A Systematic-Review|Treatment of Low Grade Glioma: Radiation Therapy Plus PCV Regimen vs Radiation Therapy only: A Systematic Review|Anti-cancer effects of selective HDAC8 PROTAC on U-87 MG glioblastoma brain cancer cell line

MO17

Mini Oral Session 17
Brain Tumor

YiChen{CHENYI}|YumikoAkita{AKITAYUMIKO}|MaoUematsu{UEMATSUMAO}|MonirujjamanBiswas{BISWASMONIRUJJAMAN}|MahoKusudo{KUSUDOMAHO}____DaisukeTakabatake{TAKABATAKEDAISUKE}|NaokiNiikura{NIIKURANAOKI}____AdrienneGWaks{WAKSADRIENNEG}|PaoloTarantino{TARANTINOPAOLO}|TianyuLi{LITIANYU}|EstherROgayo{OGAYOESTHERR}|TasnminRahnam{RAHNAMTASNMIN}|MollyKDilullo{DILULLOMOLLYK}|SherifEl-Refai{EL-REFAISHERIF}|CharlesAbbott{ABBOTTCHARLES}|SeanMBoyle{BOYLESEANM}|NeelamVDesai{DESAINEELAMV}|LauraMSpring{SPRINGLAURAM}|NadineMTung{TUNGNADINEM}|TariAKing{KINGTARIA}|IanEKrop{KROPIANE}|NabihahTayob{TAYOBNABIHAH}|ElizabethAMittendorf{MITTENDORFELIZABETHA}|SaraMTolaney{TOLANEYSARAM}|EricPWiner{WINERERICP}|HeatherAParsons{PARSONSHEATHERA}|MadokaIwase{IWASEMADOKA}|SatokoShimada{SHIMADASATOKO}|ToyoneKikumori{KIKUMORITOYONE}|DaiTakeuchi{TAKEUCHIDAI}|YukoTakano{TAKANOYUKO}|TakahiroIchikawa{ICHIKAWATAKAHIRO}|ReikoOhata{OHATAREIKO}|YuriOzaki{OZAKIYURI}|MarikoAsai{ASAIMARIKO}|MisatoYamamoto{YAMAMOTOMISATO}|GaiInaguma{INAGUMAGAI}|NaoTorii{TORIINAO}|ChihiroToyoda{TOYODACHIHIRO}|NorikazuMasuda{MASUDANORIKAZU}|HiromichiNakajima{NAKAJIMAHIROMICHI}|HirohikoMiyake{MIYAKEHIROHIKO}|NaoyaSakamoto{SAKAMOTONAOYA}|MasashiWakabayashi{WAKABAYASHIMASASHI}|MaiShimura{SHIMURAMAI}|AkiraHirota{HIROTAAKIRA}|MisaoFukuda{FUKUDAMISAO}|NobuyukiTakahashi{TAKAHASHINOBUYUKI}|ChikakoFunasaka{FUNASAKACHIKAKO}|ChihiroKondoh{KONDOHCHIHIRO}|KenichiHarano{HARANOKENICHI}|NobuakiMatsubara{MATSUBARANOBUAKI}|AkoHosono{HOSONOAKO}|YoichiNaito{NAITOYOICHI}|TatsuyaOnishi{ONISHITATSUYA}|ToruMukohara{MUKOHARATORU}|GenichiroIshii{ISHIIGENICHIRO}|KazukiNozawa{NOZAWAKAZUKI}|RikakoOgawa{OGAWARIKAKO}|MinoriAnto{ANTOMINORI}|AyaNakazawa{NAKAZAWAAYA}|RieKomaki{KOMAKIRIE}|YukaEndo{ENDOYUKA}|AyumiKataoka{KATAOKAAYUMI}|HaruruKotani{KOTANIHARURU}|AkiyoYoshimura{YOSHIMURAAKIYO}|MasayaHattori{HATTORIMASAYA}|FumikataHara{HARAFUMIKATA}____Mini Oral Session 18Breast Cancer 1 (Perioperative 1)____ctDNA among HER2+ breast cancer patients receiving neoadjuvant paclitaxel/trastuzumab/pertuzumab in the DAPHNe trial|Prognostic Impact of ER-Staining Patterns and Tils in Breast Cancer Patients with Low to Intermediate ER Expression|Prognostic Impact of Quantified Area of Residual Tumor After Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer|Knowledge of symptoms and risk factors of breast cancer among women in a low socio-economic area of Mumbai, India|Efficacy of Preoperative Pembrolizumab Plus Chemotherapy (KN-522 Regimen) for ER-Low HER2-Negative Early Breast Cancer

MO18

Mini Oral Session 18
Breast Cancer 1 (Perioperative 1)

－|AkihikoShimomura{SHIMOMURAAKIHIKO}|AyakoUeno{UENOAYAKO}|PardeepKumar{KUMARPARDEEP}|KaoriOtake{OTAKEKAORI}____ToyamaTatsuya{TATSUYATOYAMA}|KanakoSaito{SAITOKANAKO}____SatokoTakizawa{TAKIZAWASATOKO}|HiroshiKonishi{KONISHIHIROSHI}|KaoruOketani{OKETANIKAORU}|KentaroTamaki{TAMAKIKENTARO}|KojiSakae{SAKAEKOJI}|KazuoMatsuda{MATSUDAKAZUO}|YoshiakiShinden{SHINDENYOSHIAKI}|MiwaArakaki{ARAKAKIMIWA}|TeiriSagawa{SAGAWATEIRI}|KojiOhta{OHTAKOJI}|TadaoKakizoe{KAKIZOETADAO}|YumikoNomura{NOMURAYUMIKO}|KengoNagashima{NAGASHIMAKENGO}|TakahiroOchiya{OCHIYATAKAHIRO}|KenKato{KATOKEN}|MasayukiUeno{UENOMASAYUKI}|KazushigeYamaguchi{YAMAGUCHIKAZUSHIGE}|KazumichiAbe{ABEKAZUMICHI}|MasanoriAbe{ABEMASANORI}|TatehiroKagaawa{KAGAAWATATEHIRO}|KeisukeKakisaka{KAKISAKAKEISUKE}|KeikoIchimoto{ICHIMOTOKEIKO}|HiroteruKamimura{KAMIMURAHIROTERU}|YasuyukiKomiyama{KOMIYAMAYASUYUKI}|KeijiTsuji{TSUJIKEIJI}|AkemiTsutsui{TSUTSUIAKEMI}|NoriyoYamashiki{YAMASHIKINORIYO}|MasaakiWatanabe{WATANABEMASAAKI}|TakemiAkahane{AKAHANETAKEMI}|SatoshiMochida{MOCHIDASATOSHI}|AtsushiTanaka{TANAKAATSUSHI}|NaotoMorikawa{MORIKAWANAOTO}|MakotoKurihara{KURIHARAMAKOTO}|FumiyoshiKumagai{KUMAGAIFUMIYOSHI}|YukoSato{SATOYUKO}|HirokatsuChitose{CHITOSEHIROKATSU}|HiroshiHonda{HONDAHIROSHI}____Mini Oral Session 19Breast Cancer 2 (Perioperative 2)____Withdrawn|Validation of serum microRNA breast cancer markers in a screening cohort|Awareness Survey on Tamoxifen-Induced Liver Injury Among Hepatologists in Japan|Impact of Hypoxia Mimetics on Hypoxia-Inducible Factors and Gene in Primary versus Metastatic Breast Cancer Cell|Omission of pegfilgrastim in perioperative dose-dense paclitaxel therapy for breast cancer

MO19

Mini Oral Session 19
Breast Cancer 2 (Perioperative 2)

AtsushiFushimi{FUSHIMIATSUSHI}|MohamedAbdelnasser{ABDELNASSERMOHAMED}|AjitpalSingh.Brar.{BRAR.AJITPALSINGH.}|－|KevinKristianto{KRISTIANTOKEVIN}|NobuyukiTakahashi{TAKAHASHINOBUYUKI}____NorikazuMasuda{MASUDANORIKAZU}|YukinoriOzaki{OZAKIYUKINORI}____MitsuoTerada{TERADAMITSUO}|MadokaIwase{IWASEMADOKA}|TomokoShibayama{SHIBAYAMATOMOKO}|RieTahara{TAHARARIE}|YukoNakazawa{NAKAZAWAYUKO}|AsumiIesato{IESATOASUMI}|NamiYamashita{YAMASHITANAMI}|MohamedAHassanien{HASSANIENMOHAMEDA}|VivekKSingh{SINGHVIVEKK}|DomenecPuig{PUIGDOMENEC}|FernandoDharmaraja{DHARMARAJAFERNANDO}|AndreeKurniawan{KURNIAWANANDREE}|MichaelTanaka{TANAKAMICHAEL}|ChikakoFunasaka{FUNASAKACHIKAKO}|MaoUematsu{UEMATSUMAO}|MaiShimura{SHIMURAMAI}|AkiraHirota{HIROTAAKIRA}|MisaoFukuda{FUKUDAMISAO}|MikiHayakawa{HAYAKAWAMIKI}|ShotaUesawa{UESAWASHOTA}|ShuKato{KATOSHU}|KaedeBaba{BABAKAEDE}|KanakoKusuhara{KUSUHARAKANAKO}|HiromichiNakajima{NAKAJIMAHIROMICHI}|ChihiroKondoh{KONDOHCHIHIRO}|KenichiHarano{HARANOKENICHI}|AkoHosono{HOSONOAKO}|NobuakiMatsubara{MATSUBARANOBUAKI}|ToshikatsuKawasaki{KAWASAKITOSHIKATSU}|TatsuyaOhnishi{OHNISHITATSUYA}|YoichiNaito{NAITOYOICHI}|ToruMukohara{MUKOHARATORU}____Mini Oral Session 20Breast Cancer 3 (Others)____Comparative Evaluation of Japanese Breast Cancer Treatment Websites Using Large Language Models|Breast lesion classification using ultrasound videos and image-quality guided deep learning method|B-blockers for the Prevention of Anthracycline-induced Cardiotoxicity Among Adult Cancer Patients: Updated meta-analysis|Withdrawn|Cardioprotective Effect of ACEI/ARB in Breast Cancer Treated with Anthracycline: A Systematic Review and Meta analysis|Efficacy of perioperative pembrolizumab for triple-negative breast cancer with apocrine feature or metaplastic carcinoma

MO20

Mini Oral Session 20
Breast Cancer 3 (Others)

KotaKatanoda{KATANODAKOTA}|NariKureyama{KUREYAMANARI}|DaisukeOgiya{OGIYADAISUKE}|NoboruHagino{HAGINONOBORU}____MakotoUeno{UENOMAKOTO}|MinoruFukuda{FUKUDAMINORU}|ShigehisaKitano{KITANOSHIGEHISA}____TomoyukiGoto{GOTOTOMOYUKI}|RikaKizawa{KIZAWARIKA}|NaohiroOkano{OKANONAOHIRO}|KenjiTsuchihashi{TSUCHIHASHIKENJI}|YujiUehara{UEHARAYUJI}|YukinoriOzaki{OZAKIYUKINORI}|ChihiroKondoh{KONDOHCHIHIRO}|ShigemasaTakamizawa{TAKAMIZAWASHIGEMASA}|MitsuoTerada{TERADAMITSUO}|YuheiYamaguchi{YAMAGUCHIYUHEI}|MaoUematsu{UEMATSUMAO}|KyosukeSeguchi{SEGUCHIKYOSUKE}|MasahiroTorasawa{TORASAWAMASAHIRO}|MasahiroKuno{KUNOMASAHIRO}|ShigehisaKitano{KITANOSHIGEHISA}____Committee Program 1____“Tobacco harm reduction” how should we build relationships with industry in health policy?|Fact-Checking Cancer Information on Social Media in Japan|Utilization of SNS in Medical Oncology Seminars for Medical Students and Residents|Bridging Divides in Medical Communication on Social Media: Building Trust Beyond Confrontation

CP1

Committee Program 1

MelissaEastgate{EASTGATEMELISSA}|YeonHeePark{PARKYEONHEE}|EileenPoon{POONEILEEN}|Chih-HungHsu{HSUCHIH-HUNG}|IchiroKinoshita{KINOSHITAICHIRO}____IchiroKinoshita{KINOSHITAICHIRO}|HidehitoHorinouchi{HORINOUCHIHIDEHITO}____DawnQChong{CHONGDAWNQ}|ElaineLim{LIMELAINE}____Committee Program 2Educational activities on Medical Oncology in Asia-Pacific region____Oncology Education Initiatives at Medical Oncology Society in theAsia-Pacific Region - Medical Oncology Group of Australia|Crisis in Medical Oncology Fellowship Education in Korea|Educational Initiatives of Singapore Society of Oncology|Oncology Education Initiatives in Taiwan Oncology Society|Educational initiative at Japanese Society of Medical Oncology (JSMO): 2025 update

CP2

Committee Program 2
Educational activities on Medical Oncology in Asia-Pacific region

HiromizuTakahashi{TAKAHASHIHIROMIZU}|TakeshiSawada{SAWADATAKESHI}|YosukeKito{KITOYOSUKE}|TakujiSeo{SEOTAKUJI}____TeruhisaAzuma{AZUMATERUHISA}|TakakoNakajima{NAKAJIMATAKAKO}|YosukeKito{KITOYOSUKE}|TakujiSeo{SEOTAKUJI}|ReijiNamba{NAMBAREIJI}________Committee Program 3Generative AI will brighten the future of medical oncology!____Potential Contributions of Generative AI to Clinical Oncology|Expectations for AI in Drug Development|AI and young doctors|Oncologist working in a medically underserved area, pioneering with AI

CP3

Committee Program 3
Generative AI will brighten the future of medical oncology!

YuSunakawa{SUNAKAWAYU}|SeisyouKou{KOUSEISYOU}____YuSunakawa{SUNAKAWAYU}|TomokoYamazaki{YAMAZAKITOMOKO}|MakikoOno{ONOMAKIKO}|HidetoshiHayashi{HAYASHIHIDETOSHI}____HidetoshiHayashi{HAYASHIHIDETOSHI}|MakikoOno{ONOMAKIKO}|SeisyouKou{KOUSEISYOU}____Committee Program 4How do we communicate the appeal of Medical Oncology? 【JSMO University】____How do we communicate the appeal of Medical Oncology?|－

CP4

Committee Program 4
How do we communicate the appeal of Medical Oncology? 【JSMO University】

SunYoungRha{RHASUNYOUNG}____KaiTsugaru{TSUGARUKAI}____TakashiOshima{OSHIMATAKASHI}|HisateruYasui{YASUIHISATERU}|HiroshiYabusaki{YABUSAKIHIROSHI}|YoungKyuPark{PARKYOUNGKYU}|TakakiYoshikawa{YOSHIKAWATAKAKI}|KunHueiYeh{YEHKUNHUEI}|ChiaJuiYen{YENCHIAJUI}|YongjianZhou{ZHOUYONGJIAN}|WeiPengYong{YONGWEIPENG}|MatthewChauHsienNg{NGMATTHEWCHAUHSIEN}|GwoFuangHo{HOGWOFUANG}|RubiLi{LIRUBI}|XiaoFang{FANGXIAO}|PierreLeconte{LECONTEPIERRE}|PoojaBhagia{BHAGIAPOOJA}|KoheiShitara{SHITARAKOHEI}____Meet the Experts 1Perioperative Pembrolizumab + Chemotherapy for Gastric and Gastroesophageal Junction Cancer: ____Perioperative Pembrolizumab + Chemotherapy for Gastric and Gastroesophageal Junction Cancer: KEYNOTE-585 Asian Subgroup

ME1

Meet the Experts 1
Perioperative Pembrolizumab + Chemotherapy for Gastric and Gastroesophageal Junction Cancer:

ShannonNWestin{WESTINSHANNONN}____AikouOkamoto{OKAMOTOAIKOU}________Meet the Experts 2Developing a Career in Clinical Trials____Developing a Career in Clinical Trials

ME2

Meet the Experts 2
Developing a Career in Clinical Trials

Woong-YangPark{PARKWOONG-YANG}____MitsuhoImai{IMAIMITSUHO}________Meet the Experts 3Spatial transcriptome analysis on tumor microenvironment____Spatial transcriptome analysis on tumor microenvironment

ME3

Meet the Experts 3
Spatial transcriptome analysis on tumor microenvironment

UlrichKeilholz{KEILHOLZULRICH}____SusumuOkano{OKANOSUSUMU}________Meet the Experts 4Pharmacotherapy and supportive care for aging head and neck cancer patients____Pharmacotherapy and supportive care for aging head and neck cancer patients

ME4

Meet the Experts 4
Pharmacotherapy and supportive care for aging head and neck cancer patients

EdwinCuppen{CUPPENEDWIN}____KunikoSunami{SUNAMIKUNIKO}________Meet the Experts 5The pancancer genomic landscape: biology, test strategies and precision medicine guidance____The pancancer genomic landscape: biology, test strategies and precision medicine guidance

ME5

Meet the Experts 5
The pancancer genomic landscape: biology, test strategies and precision medicine guidance

ZevA.Wainberg{WAINBERGZEVA.}____TadayoshiHashimoto{HASHIMOTOTADAYOSHI}________Meet the Experts 6Precision Therapy in Gastric Cancer____Precision Therapy in Gastric Cancer

ME6

Meet the Experts 6
Precision Therapy in Gastric Cancer

WonSeogKim{KIMWONSEOG}____EiseiKondo{KONDOEISEI}________Meet the Experts 7Challenges in diagnosis and treatment of rare T-cell lymphomas____Challenges in diagnosis and treatment of rare T-cell lymphomas

ME7

Meet the Experts 7
Challenges in diagnosis and treatment of rare T-cell lymphomas

HiroshiYamamoto{YAMAMOTOHIROSHI}|RabiaBoulahssass{BOULAHSSASSRABIA}|HansWildiers{WILDIERSHANS}|KenSugimoto{SUGIMOTOKEN}____TomonoriMizutani{MIZUTANITOMONORI}|HiroshiYamamoto{YAMAMOTOHIROSHI}________SIOG/JSMO Joint SymposiumLessons to Learn from the Leading Nations in Geriatric Oncology____Current Status and Issues in Geriatric Oncology in Japan|Organizing Cancer Care for Older Adults: France’s Strategic Oncogeriatric Initiative|Implementation of geriatric assessment in Belgium|Collaboration of Oncology and Geriatrics

SJS

SIOG/JSMO Joint Symposium
Lessons to Learn from the Leading Nations in Geriatric Oncology

ChigusaMorizane{MORIZANECHIGUSA}|YoichiNaito{NAITOYOICHI}____HiroshiNishihara{NISHIHARAHIROSHI}________Medical Seminar 1Cancer Genomic Medicine guided by CGP testing____Clinical significance of CGP testing in the pancreas|Cancer Genomic Medicine guided by CGP testing - Tumor agnostic -

MeS1

Medical Seminar 1
Cancer Genomic Medicine guided by CGP testing

【Sponsored by CHUGAI PHARMACEUTICAL CO., LTD.】

YoshiakiNakamura{NAKAMURAYOSHIAKI}____EishiBaba{BABAEISHI}________Medical Seminar 2Beyond the knife: Towards the Era of Tumor-agnostic MRD Testing____－

MeS2

Medical Seminar 2
Beyond the knife: Towards the Era of Tumor-agnostic MRD Testing

【Sponsored by Myriad Genetics G.K. / SRL, Inc.】

TakashiSeto{SETOTAKASHI}|HiroshigeYoshioka{YOSHIOKAHIROSHIGE}|KazuoHasegawa{HASEGAWAKAZUO}____KazuhikoNakagawa{NAKAGAWAKAZUHIKO}________Medical Seminar 3Patients-centered treatment for EGFR mutation-positive lung cancer____－

MeS3

Medical Seminar 3
Patients-centered treatment for EGFR mutation-positive lung cancer

【Sponsored by Eli Lilly Japan K.K.】

FilippoPietrantonio{PIETRANTONIOFILIPPO}____KeiMuro{MUROKEI}________Medical Seminar 4The role of biomarkers in gastric and colon cancer treatment and future prospects____－

MeS4

Medical Seminar 4
The role of biomarkers in gastric and colon cancer treatment and future prospects

【Sponsored by Amgen K.K. Medical Department】

TakeshiKuwata{KUWATATAKESHI}____IsseiImoto{IMOTOISSEI}________Medical Seminar 5Present and future perspective on clinical practice for hereditary cancers. -The insights from SCRUM-Japan MONSTAR-SCREEN initiative-____－

MeS5

Medical Seminar 5
Present and future perspective on clinical practice for hereditary cancers. -The insights from SCRUM-Japan MONSTAR-SCREEN initiative-

【Sponsored by Myriad Genetics G.K. / SRL, Inc.】

HisatoKawakami{KAWAKAMIHISATO}____TakayukiYoshino{YOSHINOTAKAYUKI}________Medical Seminar 6Fruquintinib: Redefining Late-line Options for Colorectal Cancer____－

MeS6

Medical Seminar 6
Fruquintinib: Redefining Late-line Options for Colorectal Cancer

【Sponsored by Takeda Pharmaceutical Company Limited】

ZevA.Wainberg{WAINBERGZEVA.}____DaisukeTakahari{TAKAHARIDAISUKE}________Medical Seminar 7Leading-edge treatment strategies for HER2 negative advanced gastric cancer____－

MeS7

Medical Seminar 7
Leading-edge treatment strategies for HER2 negative advanced gastric cancer

【Sponsored by MSD K.K.】

DaisukeKotani{KOTANIDAISUKE}____YuSunakawa{SUNAKAWAYU}________Medical Seminar 8Optimal Treatment for MSI-H Colorectal Cancer ____－

MeS8

Medical Seminar 8
Optimal Treatment for MSI-H Colorectal Cancer

【Sponsored by Bristol-Myers Squibb K.K. /ONO PHARMACEUTICAL CO., LTD.】

Do-YounOh{OHDO-YOUN}____MasafumiIkeda{IKEDAMASAFUMI}________Medical Seminar 9Implementation of Immunotherapy in Biliary Tract Cancer____－

MeS9

Medical Seminar 9
Implementation of Immunotherapy in Biliary Tract Cancer

【Sponsored by AstraZeneca K.K.】

Jung-YunLee{LEEJUNG-YUN}____KanYonemori{YONEMORIKAN}________Medical Seminar 10TREATMENT LANDSCAPE IN CERVICAL CANCER: CURRENT STATUS AND FUTURE DIRECTIONS____－

MeS10

Medical Seminar 10
TREATMENT LANDSCAPE IN CERVICAL CANCER: CURRENT STATUS AND FUTURE DIRECTIONS

【Sponsored by MSD K.K.】

KathleenNMoore{MOOREKATHLEENN}____KoseiHasegawa{HASEGAWAKOSEI}________Medical Seminar 11Revolutionizing Gynecologic Cancer Treatment: Current Landscape and Future Horizons____－

MeS11

Medical Seminar 11
Revolutionizing Gynecologic Cancer Treatment: Current Landscape and Future Horizons

【Sponsored by Takeda Pharmaceutical Company Limited Medical Affairs】

ShannonNevilleWestin{WESTINSHANNONNEVILLE}____AikouOkamoto{OKAMOTOAIKOU}________Medical Seminar 12Combination strategies for the treatment of advanced and recurrent endometrial cancer____－

MeS12

Medical Seminar 12
Combination strategies for the treatment of advanced and recurrent endometrial cancer

【Sponsored by AstraZeneca K.K.】

SunYoungRha{RHASUNYOUNG}____NarikazuBoku{BOKUNARIKAZU}________Medical Seminar 13New biomarker based treatment strategies for metastatic gastric cancer____－

MeS13

Medical Seminar 13
New biomarker based treatment strategies for metastatic gastric cancer

【Sponsored by Astellas Pharma Inc.】

KazushigeWakuda{WAKUDAKAZUSHIGE}|KoheiOtsubo{OTSUBOKOHEI}____IsamuOkamoto{OKAMOTOISAMU}________Evening Seminar 1Treatment Strategies for ALK-Positive Lung Cancer____Treatment Sequence for advanced ALK-positive non-small cell lung cancer|First-line treatment for advanced ALK-positive non-small cell lung cancer

ES1

Evening Seminar 1
Treatment Strategies for ALK-Positive Lung Cancer

【Sponsored by Takeda Pharmaceutical Company Limited】

BhumsukKeam{KEAMBHUMSUK}|MakotoTahara{TAHARAMAKOTO}____SusumuOkano{OKANOSUSUMU}________Evening Seminar 2Thyroid Cancer Update in South Korea and Japan____Current status, Issues and Future Prospects of Genomics Medicine for Thyroid Cancer in South Korea|Current status, Issues and Future Prospects of Genomics Medicine for Thyroid Cancer in Japan

ES2

Evening Seminar 2
Thyroid Cancer Update in South Korea and Japan

【Sponsored by Novartis Pharma K.K.】

TomohiroSakamoto{SAKAMOTOTOMOHIRO}|YukoOya{OYAYUKO}____MiyakoSatouchi{SATOUCHIMIYAKO}________Evening Seminar 3The Latest Treatment Strarategy in Lung Cancer～Diagnosis and Therapy for Patient’s Life～____Genetic Testing in Non-Small Cell Lung Cancer ～To close encounters of the Rare mutations～|Close Encounters of the Rare mutations～Focus on MET～

ES3

Evening Seminar 3
The Latest Treatment Strarategy in Lung Cancer～Diagnosis and Therapy for Patient’s Life～

【Sponsored by TAIHO PHARMACEUTICAL CO., LTD.】

NobuhikoSeki{SEKINOBUHIKO}____SatoshiOizumi{OIZUMISATOSHI}________Evening Seminar 4Latest Clinical Evidence & Future Outlook in NSCLC treatment____－

ES4

Evening Seminar 4
Latest Clinical Evidence & Future Outlook in NSCLC treatment

【Sponsored by MSD K.K.】

KazunoriHonda{HONDAKAZUNORI}|TsubasaTamura{TAMURATSUBASA}____HidetoshiHayashi{HAYASHIHIDETOSHI}________Evening Seminar 5Shifting the Focus: Financial and Time Toxicity in Cancer Care____Financial and Time toxicity of cancer|How to evaluate the value of reducing time toxicity in cancer chemotherapy

ES5

Evening Seminar 5
Shifting the Focus: Financial and Time Toxicity in Cancer Care

【Sponsored by Kyowa Kirin Co Ltd】

HidehitoHorinouchi{HORINOUCHIHIDEHITO}|SatoshiMorita{MORITASATOSHI}____SeijiYano{YANOSEIJI}________Evening Seminar 6Treatment strategies for non-small cell lung cancer from clinical and statistical interpretations____Treatment strategy of ALK-positive NSCLC using Alectinib|Unveiling PFS and OS in Advanced Lung Cancer Clinical Trials from Medical Statistics

ES6

Evening Seminar 6
Treatment strategies for non-small cell lung cancer from clinical and statistical interpretations

【Sponsored by CHUGAI PHARMACEUTICAL CO., LTD.】

DaisukeKotani{KOTANIDAISUKE}____KeishoChin{CHINKEISHO}________Evening Seminar 7Treatment strategy for esophageal cancer in 1st line setting for long survival____－

ES7

Evening Seminar 7
Treatment strategy for esophageal cancer in 1st line setting for long survival

【Sponsored by MSD K.K.】

KanYonemori{YONEMORIKAN}____MasanobuTakahashi{TAKAHASHIMASANOBU}________Evening Seminar 8New treatment option for alveolar soft part sarcoma (ASPS)～Efficacy and safety of Atezolizumab～____－

ES8

Evening Seminar 8
New treatment option for alveolar soft part sarcoma (ASPS)～Efficacy and safety of Atezolizumab～

【Sponsored by CHUGAI PHARMACEUTICAL CO., LTD.】

MakotoUeno{UENOMAKOTO}|StephenL.Chan{CHANSTEPHENL.}____MasafumiIkeda{IKEDAMASAFUMI}________Evening Seminar 9Cutting edge of Hepatocellular Carcinoma Treatment: Treatment Strategies based on Clinical trials and Real World Data____Integration of Clinical Trial and Real World Data ~ Optimal Treatment Strategy for Hepatocellular Carcinoma Guided by Data Originating in Japan ~|Latest treatment strategy on HCC at the era of cancer immunotherapy

ES9

Evening Seminar 9
Cutting edge of Hepatocellular Carcinoma Treatment: Treatment Strategies based on Clinical trials and Real World Data

【Sponsored by CHUGAI PHARMACEUTICAL CO., LTD.】

ChisatoNakamura{NAKAMURACHISATO}|HiroyaTaniguchi{TANIGUCHIHIROYA}____KenseiYamaguchi{YAMAGUCHIKENSEI}________Evening Seminar 10Personalized therapy for colorectal cancer ～Chemotherapy and supportive care for individual patients～____Self-care support for skin symptoms: how to personalize considering patient adherence|The Frontiers of Biomarker-Based Personalized Therapy for Colorectal Cancer

ES10

Evening Seminar 10
Personalized therapy for colorectal cancer ～Chemotherapy and supportive care for individual patients～

【Sponsored by Merck Biopharma Co., Ltd.】

YoshiyukiKizawa{KIZAWAYOSHIYUKI}____JiichiroSasaki{SASAKIJIICHIRO}________Evening Seminar 11Towards high-quality cancer patient support: perspectives on disease understanding and treatment decisions from both patients and healthcare professionals____－

ES11

Evening Seminar 11
Towards high-quality cancer patient support: perspectives on disease understanding and treatment decisions from both patients and healthcare professionals

【Sponsored by CHUGAI PHARMACEUTICAL CO., LTD.】

Giuseppe.Curigliano{CURIGLIANOGIUSEPPE}____ToshimiTakano{TAKANOTOSHIMI}________Evening Seminar 12The new wave of ADC in metastatic Triple Negative Breast Cancer____－

ES12

Evening Seminar 12
The new wave of ADC in metastatic Triple Negative Breast Cancer

【Sponsored by Gilead Sciences K.K.】

YoshitakaZenke{ZENKEYOSHITAKA}|KoichiAzuma{AZUMAKOICHI}____SeijiNiho{NIHOSEIJI}________Evening Seminar 13ICI Treatments strategies in Advanced Lung Cancer for diverse groups of patients____POSEIDON’s usefulness considered, through various factors including but not limited to PD-L1 expression|CASPIAN’s usefulness considered, through evidence for various patient background

ES13

Evening Seminar 13
ICI Treatments strategies in Advanced Lung Cancer for diverse groups of patients

【Sponsored by AstraZeneca K.K.】

－____－________PAP Orientation①____PAP Orientation①

PAP-O1

PAP Orientation①

－____－________PAP Special Lecture ①____パネルディスカッション：がん患者の声を聴く

PAP-SS1

PAP Special Lecture ①

AkihiroSakurai{SAKURAIAKIHIRO}____－________PAP Basic Lecture ①____遺伝性腫瘍の診療はどこまで進んだのか【カリキュラムコード：がん-1】

PAP-BL1

PAP Basic Lecture ①

NaomiSakurai{SAKURAINAOMI}____－________PAP Special Lecture ②____企業におけるがん患者の就労支援～がん経験者コミュニティ活動【カリキュラムコード：がん-2】

PAP-SS2

PAP Special Lecture ②

YasushiGoto{GOTOYASUSHI}____－________PAP Luncheon Seminar ①____がん薬物療法のコストを評価する～JCOG医療経済小委員会の活動から

PAP-LS1

PAP Luncheon Seminar ①

KeijiOkinaka{OKINAKAKEIJI}____－________PAP Basic Lecture ②____発熱性好中球減少症（FN）診療ガイドラインの改訂～最新のエビデンス【カリキュラムコード：がん-1】

PAP-BL2

PAP Basic Lecture ②

ToshimiTakano{TAKANOTOSHIMI}____－________PAP Basic Lecture ③____がんサバイバーの心臓を守る～カルディオオンコロジー（腫瘍循環器）とは【カリキュラムコード：がん-1】

PAP-BL3

PAP Basic Lecture ③

－____KiyotakaWatanabe{WATANABEKIYOTAKA}|NoriyukiKatsumata{KATSUMATANORIYUKI}|JiichiroSasaki{SASAKIJIICHIRO}|HisakazuNishimori{NISHIMORIHISAKAZU}________PAP Special Lecture ③____Highlights of the day～学術集会 1 日目のポイント

PAP-SS3

PAP Special Lecture ③

－____－________Opening Remarks____－

NO1

Opening Remarks

－____－________Presidential Sessionlive streaming____－

NO2

Presidential Session
live streaming